

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) B9

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number
WO 01/04140 A1

(51) International Patent Classification⁷: C07K 7/06, 7/08, C07H 21/00, A61K 38/08, 38/10, 38/16

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/NZ00/00121

(22) International Filing Date: 10 July 2000 (10.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

09/351,348 12 July 1999 (12.07.1999) US

09/450,072 29 November 1999 (29.11.1999) US

(71) Applicant (for all designated States except US): GENESIS RESEARCH & DEVELOPMENT CORPORATION LIMITED [NZ/NZ]; 1 Fox Street, Parnell, Auckland (NZ).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventor; and

(75) Inventor/Applicant (for US only): DELCAYRE, Alain [FR/US]; 3035 Kelton Avenue, Los Angeles, CA 90034 (US).

(74) Agents: BENNETT, Michael, Roy et al.; West-Walker Bennett, Mobil on the Park, 157 Lambton Quay, Wellington (NZ).



WO 01/04140 A1

(54) Title: COMPOUNDS FOR TREATMENT OF INFECTIOUS AND IMMUNE SYSTEM DISORDERS AND METHODS FOR THEIR USE

(57) Abstract: The present invention provides polypeptides comprising an immunogenic epitope of a *M. vaccae* protein, polynucleotides encoding such polypeptides, and fusion proteins comprising at least one such polypeptide, together with DNA constructs comprising at least one inventive polynucleotide. Compositions comprising such polypeptides, polynucleotides, fusion proteins and/or DNA constructs may be employed in the treatment of infectious diseases and immune disorders.

79

COMPOUNDS FOR TREATMENT OF INFECTIOUS AND IMMUNE SYSTEM
DISORDERS AND METHODS FOR THEIR USE

5 Technical Field

The present invention relates generally to the detection, treatment and prevention of infectious diseases. In particular, the invention is related to compounds comprising immunogenic epitopes isolated from *Mycobacterium vaccae*, and the use of such compounds in vaccination or immunotherapy against infectious disease, including mycobacterial infections 10 such as infection with *Mycobacterium tuberculosis* or *Mycobacterium avium*, and in certain treatments for immune disorders and cancer.

Background of the Invention

The present invention relates generally to the treatment and prevention of infectious 15 diseases, and to the treatment of certain immune disorders and cancers. In particular, the invention is related to compounds and methods for the treatment and prevention of mycobacterial infections, including infection with *Mycobacterium tuberculosis* or *Mycobacterium avium*.

Tuberculosis is a chronic, infectious disease that is caused by infection with 20 *Mycobacterium tuberculosis* (*M. tuberculosis*). It is a major disease in developing countries, as well as an increasing problem in developed areas of the world, with about 8 million new cases and 3 million deaths each year. Although the infection may be asymptomatic for a considerable period of time, the disease is most commonly manifested as a chronic inflammation of the lungs, resulting in fever and respiratory symptoms. If left untreated, significant morbidity and death 25 may result.

Although tuberculosis can generally be controlled using extended antibiotic therapy, such treatment is not sufficient to prevent the spread of the disease. Infected individuals may be asymptomatic, but contagious, for some time. In addition, although compliance with the treatment regimen is critical, patient behaviour is difficult to monitor. Some patients do not

complete the course of treatment, which can lead to ineffective treatment and the development of drug resistant mycobacteria.

Inhibiting the spread of tuberculosis requires effective vaccination and accurate, early diagnosis of the disease. Currently, vaccination with live bacteria is the most efficient method 5 for inducing protective immunity. The most common mycobacterium employed for this purpose is *Bacillus Calmette-Guerin (BCG)*, an avirulent strain of *Mycobacterium bovis*. However, the safety and efficacy of BCG is a source of controversy and some countries, such as the United States of America, do not vaccinate the general public. Diagnosis of *M. tuberculosis* infection is commonly achieved using a skin test, which involves intradermal exposure to tuberculin PPD 10 (protein-purified derivative). Antigen-specific T cell responses result in measurable induration at the injection site by 48-72 hours after injection, thereby indicating exposure to mycobacterial antigens. Sensitivity and specificity have, however, been a problem with this test, and individuals vaccinated with BCG cannot be distinguished from infected individuals.

A less well-known mycobacterium that has been used for immunotherapy for 15 tuberculosis, and also leprosy, is *Mycobacterium vaccae*, which is non-pathogenic in humans. However, there is less information on the efficacy of *M. vaccae* compared with BCG, and it has not been used widely to vaccinate the general public. *M. bovis* BCG and *M. vaccae* are believed to contain antigenic compounds that are recognised by the immune system of individuals exposed to infection with *M. tuberculosis*.

20 Several patents and other publications disclose treatment of various conditions by administering mycobacteria, including *M. vaccae*, or certain mycobacterial fractions. International Patent Publication WO 91/02542 discloses treatment of chronic inflammatory disorders in which a patient demonstrates an abnormally high release of IL-6 and/or TNF or in which the patient's IgG shows an abnormally high proportion of agalactosyl IgG. Among the 25 disorders mentioned in this publication are psoriasis, rheumatoid arthritis, mycobacterial disease, Crohn's disease, primary biliary cirrhosis, sarcoidosis, ulcerative colitis, systemic lupus erythematosus, multiple sclerosis, Guillain-Barre syndrome, primary diabetes mellitus, and some aspects of graft rejection. The therapeutic agent preferably comprises autoclaved *M. vaccae* administered by injection in a single dose.

U.S. Patent 4,716,038 discloses diagnosis of, vaccination against and treatment of autoimmune diseases of various types, including arthritic diseases, by administering mycobacteria, including *M. vaccae*. U.S. Patent 4,724,144 discloses an immunotherapeutic agent comprising antigenic material derived from *M. vaccae* for treatment of mycobacterial diseases, especially tuberculosis and leprosy, and as an adjuvant to chemotherapy. International Patent Publication WO 91/01751 discloses the use of antigenic and/or immunoregulatory material from *M. vaccae* as an immunoprophylactic to delay and/or prevent the onset of AIDS. International Patent Publication WO 94/06466 discloses the use of antigenic and/or immunoregulatory material derived from *M. vaccae* for therapy of HIV infection, with or without AIDS and with or without associated tuberculosis.

Traditional vaccines contain the disease-causing organism (or a component thereof) in either attenuated or killed form. As an alternative approach to traditional vaccines, DNA vaccines have been developed for diseases as diverse as AIDS, influenza, cancer and malaria. Clinical trials of DNA vaccines are in progress for a number of these diseases. A typical DNA vaccine consists of DNA encoding an antigen cloned in a non-active plasmid carrier. Expression of the antigen encoded by the vaccine DNA is usually under control of a strong promoter, such as human β -actin, Rous sarcoma virus (RSV) or CMV promoter (Ramsay AJ, *et al. Immunology and Cell Biology* 75:360-363, 1997). The first experimental evidence that DNA vaccines were able to induce the desired immune response was produced by Tang *et al.* (Tang D-C, *et al. Nature* 356:152-154, 1992). In these experiments, mice inoculated with plasmids containing the gene encoding for human growth hormone developed specific primary antibody responses.,

Immune responses to two DNA vaccines containing genes from *M. tuberculosis* have been evaluated in animal models. The first vaccine contained the gene coding for the GroEL stress protein (65 kDa protein; Tascon RE, *et al. Nature Med.* 2:888-892, 1996). Mice injected with this DNA vaccine were protected at a level equivalent to mice receiving the traditional BCG vaccine. The second DNA vaccine against *M. tuberculosis* contained DNA encoding an antigen from the antigen 85 complex and similar results to the study by Tang *et al.* were obtained (Huygen K, *et al. Nature Med.* 2:893-898, 1996). U.S. Patent 5,736,524 discloses vaccination of domestic mammals or livestock against infection by *M. tuberculosis* or *M. bovis* by

administering a polynucleotide tuberculosis vaccine comprising the *M. tuberculosis* antigen 85 gene operably linked to transcription regulatory elements.

The first human DNA vaccine trial was reported recently (Wang R, et al. *Science* 282:476-80, 1998). In this trial, an antigen from *Plasmodium falciparum*, the causative agent of malaria, was injected into healthy volunteers. The desired immune response was elicited, as demonstrated by the presence of cytotoxic T (CD8⁺) lymphocytes (CTL), suggesting that the immune system would be able to clear parasites from infected patients. Safety and immunogenicity of a human DNA vaccine against HIV-1 infection was determined in a trial performed by McGregor et al. (*J. Infect. Dis.* 178:92-100, 1998). Experimental data from other DNA vaccine experiments has also suggested that antibodies, MHC class I-restricted CD8⁺ CTL and class II-restricted CD4⁺ helper T cells are produced following injection with DNA vaccines (Ramsay, AJ et al. *Immunology and Cell Biology* 75:360-363, 1997).

DNA vaccines have distinct advantages over more traditional vaccines containing killed or attenuated organisms. DNA vaccination induces immune responses that are long-lived and therefore only a single inoculation may be required. DNA encoding a number of antigens may be incorporated into a single plasmid thereby providing protection against a number of diseases. The technology for DNA vaccine production is relatively simple and the same technology can be used to produce all vaccines, with a resulting cheaper production cost. Delivery of efficacious traditional vaccines to the patient are dependent on maintaining an unbroken "cold chain" from manufacturer to clinic. DNA vaccines produced in solution or in dried form are not sensitive to storage conditions.

Recently, alternative ways of constructing and applying DNA vaccines have been developed. In one of the techniques, called Somatic Transgene Immunisation (STI), the plasmid DNA carrying an immunoglobulin heavy chain gene under the control of tissue-specific regulatory elements was inoculated directly into the spleen of mice, with subsequent expression of the antigen on the surface of B-cells (Xiong S, et al. *Proc. Natl. Acad. Sci. USA* 94:6352-6357, 1997). These B cells produced antibodies against the expressed antigen, leading to an immune response. Subsequent studies showed that STI induced persistent immunologic memory for up to 2 years (Gerloni M, et al. *Vaccine* (2-3):293-297, 1998).

Expression Library Immunization (ELI) is another technique employing DNA vaccines (Barry MA, *et al.* *Nature* 377:632-635, 1995). In this technique, fragments of the complete genome of a pathogen are cloned into a vector and used as vaccine. Selection of protective antigen(s), particularly those inducing CTL, is done by screening and re-screening pools of 5 clones until single clones can be identified. The polynucleotide or polypeptide identified may then be incorporated into a proven delivery system.

Progress on the development of an epitope-based vaccine for the treatment and prevention of HIV infection by scientists at Epimmune Inc. (San Diego, CA), has recently been published (Ishioka GY, *et al.*, *Journal of Immunology* 162:3915-3925, 1999).

10 There remains a need in the art for effective compounds and methods for preventing and treating infectious disorders, such as tuberculosis and other mycobacterial infections in humans and in domestic mammals or livestock, and for the treatment of certain immune system-related disorders.

15 **Summary of the Invention**

Briefly stated, the present invention provides compounds and methods for the prevention and treatment of infectious diseases, such as mycobacterial infections, and for the treatment of immune disorders and cancers.

20 In a first aspect, isolated polynucleotides are provided that are derived from the *M. vaccae* genome. These polynucleotides encode polypeptide epitopes selected on the basis of their immunogenic properties as illustrated by results from a number of immunological assays. In specific embodiments, the inventive polynucleotides comprise a sequence selected from the group consisting of: (a) sequences provided in SEQ ID NO: 8-21; (b) sequences having at least 25 50%, 75% or 90% identical residues to a sequence of SEQ ID NO: 8-21 as determined using the computer algorithm BLASTN; and (c) complements of the sequences of (a) and (b).

25 In a second aspect, the invention provides isolated polypeptides comprising an immunogenic epitope of a *M. vaccae* antigen. In specific embodiments, the inventive polypeptides comprise a sequence selected from the group consisting of: (a) sequences provided in SEQ ID NO: 61-77; and (b) sequences having at least 50%, 75% or 90% identical residues to 30 a sequence of SEQ ID NO: 61-77 as determined using the computer algorithm FASTX.

DNA constructs comprising at least one of the inventive polynucleotides, and host cells transformed or transfected with such DNA constructs are also provided.

In another aspect, the present invention provides fusion proteins comprising at least one polypeptide of the present invention.

5 Within other aspects, the present invention provides compositions that comprise at least one of the inventive polypeptides, polynucleotides, fusion proteins or DNA constructs, and a physiologically acceptable carrier. The invention also provides compositions comprising at least one of the above polypeptides, polynucleotides, fusion proteins or DNA constructs and an immunostimulant.

10 In yet another aspect, methods are provided for enhancing an immune response in a patient, comprising administering to a patient an effective amount of one or more of the above compositions. In one embodiment, the immune response is a Th1 response.

15 In further aspects of this invention, methods are provided for the treatment of a disorder in a patient, comprising administering to the patient a composition of the present invention. In certain embodiments, the disorder is selected from the group consisting of immune disorders, infectious diseases and cancer.

These and other aspects of the present invention will become apparent upon reference to the following detailed description. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

20

Brief Description of the Drawings

25 Figs. 1A-F illustrate the induction of protective immunity, measured as a decrease in *M. tuberculosis* CFU in lung and spleen homogenates of BALB/cByJ mice, by vaccination with *M. bovis* BCG (Figs. 1A and D, respectively), with ME/D DNA (Figs. 1B and E, respectively), or with rME/D (Fig. 1C and F, respectively).

Figs. 2A-D show the proliferative responses of lymph node cells from BALB/cByJ mice immunized subcutaneously with rME/A (Fig. 2A), rME/B (Fig. 2B) or rME/D (Fig. 2C). Control mice were immunized with PBS (Fig. 2D).

Figs. 3A-D illustrate IFN- γ secretion by lymph node cells from BALB/cByJ mice immunized subcutaneously with recombinant multi-epitope constructs rME/A (Fig. 3A), rME/B (Fig. 3B) or rME/D (Fig. 3C). Control mice were immunized with PBS (Fig. 3D).

Fig. 4A demonstrates the proliferative responses of lymph node cells from BALB/cByJ mice immunized with rME/A, rME/D or ME/D DNA by three different routes of immunization. The proliferative response of lymph node cells from control mice immunized with PBS is shown in Fig. 4B.

Fig. 5A demonstrates the level of IFN- γ secretion by lymph node cells from BALB/cByJ mice immunized with rME/A, rME/D or ME/D DNA by three different routes of immunization.

10 The level of IFN- γ secretion by control mice immunized with PBS is shown in Fig. 5B.

Fig. 6A show the contribution of single epitopes to the proliferative responses of lymph node cells from BALB/cByJ mice immunized with rME/A, rME/D or ME/D DNA by three different routes of immunization. The proliferative response of lymph node cells from control mice immunized with PBS is shown in Fig. 6B.

15 Fig. 7A demonstrates contribution of single epitopes to the level of IFN- γ secretion by lymph node cells from BALB/cByJ mice immunized with rME/A, rME/D or ME/D DNA by three different routes of immunization. The level of IFN- γ secretion by control mice immunized with PBS is shown in Fig. 7B.

20 Figs. 8A and B illustrate the titre and subclass of anti-ME antibodies in the serum of mice immunized with ME/D DNA that reacted with rME/A and rME/D *in vitro*. The titres of IgG1 antibodies are shown in Fig. 8A, with the titre of IgG2a antibodies being shown in Fig. 8B.

Figs. 9A-C show the IFN- γ secretion by memory splenocytes from BALB/cByJ mice immunized with recombinant single epitopes (Fig. 9B) or rME/D (Fig. 9C). IFN- γ secretion by splenocytes after stimulation with controls is shown in Fig. 9A.

25 Figs. 10A and B demonstrate the IFN- γ secretion (Fig. 10A) and proliferative response (Fig. 10B) by human PBMC after stimulation *in vitro* with rME/A, rME/B or rME/D.

Figs. 11A and B demonstrate the IFN- γ secretion (Fig. 11A) and proliferative response (Fig. 11B) by human PBMC after stimulation *in vitro* with eight recombinant single epitopes.

30 Detailed Description of the Invention

As noted above, the present invention is generally directed to compositions and methods for preventing and treating disorders including infectious diseases and certain immune disorders and cancers. Examples of such disorders include, but are not limited to, mycobacterial infections, including *M. tuberculosis* and *M. avium* infections; and disorders in which the 5 stimulation of a Th1 immune response is beneficial, including (but not limited to) psoriasis and allergic rhinitis.

Certain pathogens, such as *M. tuberculosis*, as well as certain cancers, are effectively contained by an immune attack directed by CD4⁺ T cells, known as cell-mediated immunity. Other pathogens, such as poliovirus, also require antibodies, produced by B cells, for 10 containment. These different classes of immune attack (T cell or B cell) are controlled by different subpopulations of CD4⁺ T cells, commonly referred to as Th1 and Th2 cells.

The two types of Th cell subsets have been well characterized in a murine model and are defined by the cytokines they release upon activation. The Th1 subset secretes IL-2, IFN- γ and tumor necrosis factor, and mediates macrophage activation and delayed-type hypersensitivity 15 response. The Th2 subset releases IL-4, IL-5, IL-6 and IL-10, which stimulate B cell activation. The Th1 and Th2 subsets are mutually inhibiting, so that IL-4 inhibits Th1-type responses, and IFN- γ inhibits Th2-type responses. Similar Th1 and Th2 subsets have been found in humans, with release of the identical cytokines observed in the murine model. Amplification of Th1-type immune responses is central to a reversal of disease state in many disorders, including 20 disorders of the respiratory system such as tuberculosis, sarcoidosis, asthma, allergic rhinitis and lung cancers.

In one aspect, the compositions of the present invention include polypeptides that comprise at least one immunogenic epitope of a *M. vaccae* antigen, or a variant thereof. In specific embodiments, the inventive polypeptides comprise a sequence provided in SEQ ID 25 NO: 61-77. Such polypeptides stimulate T cell proliferation, and/or interferon gamma secretion from T cells of individuals exposed to *M. tuberculosis*.

As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full-length proteins (*i.e.*, antigens), wherein the amino acid residues are linked by covalent peptide bonds. Thus, a polypeptide comprising an immunogenic epitope of one of the 30 above antigens may consist entirely of the immunogenic epitope, or may contain additional

sequences. The additional sequences may be derived from the native *M. vaccae* antigen or may be heterologous, and such sequences may (but need not) be immunogenic.

“Immunogenic,” as used herein, refers to the ability to elicit an immune response in a patient, such as a human, or in a biological sample. In particular, an immunogenic epitope is that 5 portion of a polypeptide that is capable of stimulating cell proliferation, interleukin-12 production or interferon- γ production in biological samples comprising one or more cells selected from the group of T cells, NK cells, B cells and macrophages, where the cells are derived from a mycobacteria-immune individual. In general, an immunogenic epitope will stimulate proliferation of PBMC from mycobacteria-immune individuals at levels at least two-fold greater than that observed in control PBMC, determined using assay techniques detailed 10 below in Example 1. Alternatively, or additionally, an immunogenic epitope will stimulate the production of interferon- γ in PBMC from mycobacteria-immune individuals at levels that are at least two-fold greater than those observed in control cells as determined by at least a two-fold increase in OD in an ELISA assay as detailed in Example 1. A mycobacteria-immune individual 15 is one who is considered to be resistant to the development of mycobacterial infection by virtue of having mounted an effective T cell response to *M. tuberculosis*, to environmental saprophytes, or to BCG. Such individuals may be identified based on a strongly positive (*i.e.*, greater than about 10 mm diameter induration) intradermal skin test response to tuberculosis proteins (PPD), and an absence of any symptoms of tuberculosis infection. Polypeptides comprising at least an 20 immunogenic epitope of one or more *M. vaccae* antigens may generally be used to induce protective immunity against tuberculosis in a patient and/or to stimulate an immune response in a patient.

In another aspect, the compositions of the present invention comprise isolated polynucleotides that encode an immunogenic epitope of a *M. vaccae* antigen. In specific 25 embodiments, the inventive polynucleotides comprise a sequence of SEQ ID NO: 5-21. Complements of the inventive isolated polynucleotides, reverse complements of such isolated polynucleotides and reverse sequences of such isolated polynucleotides are also provided, together with variants of such sequences. The present invention also encompasses polynucleotide sequences that differ from the disclosed sequences but which, due to the

degeneracy of the genetic code, encode a polypeptide which is the same as that encoded by a polynucleotide sequence disclosed herein.

The term "polynucleotide(s)," as used herein, means a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases and includes DNA and corresponding RNA molecules, including HnRNA and mRNA molecules, both sense and anti-sense strands, and comprehends cDNA, genomic DNA and recombinant DNA, as well as wholly or partially synthesized polynucleotides. An HnRNA molecule contains introns and corresponds to a DNA molecule in a generally one-to-one manner. An mRNA molecule corresponds to an HnRNA and/or DNA molecule from which the introns have been excised. A polynucleotide may consist 10 of an entire gene, or any portion thereof. Operable anti-sense polynucleotides may comprise a fragment of the corresponding polynucleotide, and the definition of "polynucleotide" therefore includes all such operable anti-sense fragments. Anti-sense polynucleotides and techniques involving anti-sense polynucleotides are well known in the art and are described, for example, in Robinson-Benion *et al.* "Antisense techniques," *Methods in Enzymol.* 254:363-375, 1995; and 15 Kawasaki *et al.* *Artific. Organs* 20:836-848, 1996.

The definition of the terms "complement", "reverse complement" and "reverse sequence", as used herein, is best illustrated by the following example. For the sequence 5' AGGACC 3', the complement, reverse complement and reverse sequence are as follows:

complement	3' TCCTGG 5'
reverse complement	3' GGTCTT 5'
reverse sequence	5' CCAGGA 3'.

All of the polynucleotides and polypeptides described herein are isolated and purified, as those terms are commonly used in the art.

The compositions and methods of this invention also encompass variants of the above 25 polypeptides and polynucleotides. Variants may be naturally occurring allelic variants, or non-naturally occurring variants. As used herein, the term "variant" covers any sequence which has at least about 30%, more preferably at least about 50%, more preferably yet at least about 75% and most preferably at least about 90% identical residues (either nucleotides or amino acids) to a sequence of the present invention. The percentage of identical residues is determined by 30 aligning the two sequences to be compared, determining the number of identical residues in the

aligned portion, dividing that number by the total length of the inventive, or queried, sequence and multiplying the result by 100.

Polynucleotide or polypeptide sequences may be aligned, and percentage of identical nucleotides in a specified region may be determined against another polynucleotide, using computer algorithms that are publicly available. Two exemplary algorithms for aligning and identifying the similarity of polynucleotide sequences are the BLASTN and FASTA algorithms. The similarity of polypeptide sequences may be examined using the BLASTP and FASTX algorithms. Both the BLASTN and BLASTP software are available on the NCBI anonymous FTP server (<ftp://ncbi.nlm.nih.gov>) under `/blast/executables/`. The BLASTN algorithm Version 2.0.6 [Sep-16-1998], set to the default parameters described in the documentation and distributed with the algorithm, is preferred for use in the determination of variants according to the present invention. The use of the BLAST family of algorithms, including BLASTN and BLASTP, is described at NCBI's website at URL <http://www.ncbi.nlm.nih.gov/BLAST/newblast.html> and in the publication of Altschul, Stephen F, *et al.* "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," *Nucleic Acids Res.* 25:3389-3402, 1997. The computer algorithm FASTA is available on the Internet at the ftp site <ftp://ftp.virginia.edu/pub/fasta/>. Version 3.1t11 August 1998, of the FASTA and FASTX algorithms, set to the default parameters described in the documentation and distributed with the algorithms, are preferred for use in the determination of variants according to the present invention. The use of the FASTA algorithm is described, for example, in Pearson WR and Lipman DJ. *Proc. Natl. Acad. Sci. USA* 85:2444-2448, 1988; and Pearson WR. *Methods in Enzymol.* 183:63-98, 1990. The use of the FASTX algorithm is described, for example, in Pearson WR, *et al.*, *Genomics* 46:24-36, 1997.

The following running parameters are preferred for determination of alignments and similarities using BLASTN that contribute to the E values and percentage identity: Unix running command: `blastall -p blastn -d embldb -e 10 -G 0 -E 0 -r 1 -v 30 -b 30 -i queryseq -o results`; and parameter default values: -p Program Name [String]; -d Database [String]; -e Expectation value (E) [Real]; -G Cost to open a gap (zero invokes default behavior) [Integer]; -E Cost to extend a gap (zero invokes default behavior) [Integer]; -r Reward for a nucleotide match (BLASTN only) [Integer]; -v Number of one-line descriptions (V) [Integer]; -b Number of

alignments to show (B) [Integer]; -i Query File [File In]; -o BLAST report Output File [File Out] Optional. For BLASTP the following running parameters are preferred: blastall -p blastp -d swissprotdb -e 10 -G 0 -E 0 -v 30 -b 30 -i queryseq -o results; -p Program Name [String]; -d Database [String]; -e Expectation value (E) [Real]; -G Cost to open a gap (zero invokes default behavior) [Integer]; -E Cost to extend a gap (zero invokes default behavior) [Integer]; -v Number of one-line descriptions (v) [Integer]; -b Number of alignments to show (b) [Integer]; -I Query File [File In]; -o BLAST report Output File [File Out] Optional.

For determination of alignments and similarities using FASTX, the following UNIX command is preferred: fastx -E 10 -b 30 -H queryseq > output, while for FASTA, the following 10 UNIX command is preferred: fasta -E 2 -b 30 -H -n queryseq > output.

The "hits" to one or more database sequences by a queried sequence produced by BLASTN, BLASTP, FASTA, FASTX or a similar algorithm, align and identify similar portions of sequences. The hits are arranged in order of the degree of similarity and the length of sequence overlap. Hits to a database sequence generally represent an overlap over only a 15 fraction of the sequence length of the queried sequence.

The BLASTN and FASTA algorithms also produce "Expect" values for alignments. The Expect value (E) indicates the number of hits one can "expect" to see over a certain number of contiguous sequences by chance when searching a database of a certain size. The Expect value is used as a significance threshold for determining whether the hit to a database, such as the 20 preferred EMBL database, indicates true similarity. For example, an E value of 0.1 assigned to a hit is interpreted as meaning that in a database of the size of the EMBL database, one might expect to see 0.1 matches over the aligned portion of the sequence with a similar score simply by chance. By this criterion, the aligned and matched portions of the sequences then have a probability of 90% of being the same. For sequences having an E value of 0.01 or less over 25 aligned and matched portions, the probability of finding a match by chance in the EMBL database is 1% or less using the BLASTN or FASTA algorithm.

According to one embodiment, "variant" polynucleotides, with reference to each of the polynucleotides of the present invention, preferably comprise sequences having the same number or fewer nucleic acids than each of the polynucleotides of the present invention and producing an 30 E value of 0.01 or less when compared to the polynucleotide of the present invention. That is, a

variant polynucleotide is any sequence that has at least a 99% probability of being the same as the polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at the default parameters. According to a preferred embodiment, a variant polynucleotide is a sequence having the same number or fewer nucleic acids than a polynucleotide of the present invention that has at least a 99% probability of being the same as the polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at the default parameters.

In certain embodiments, variant polynucleotide sequences hybridize to the recited polynucleotide sequence under stringent conditions. As used herein, "stringent conditions" refers to prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at 65°C, 6X SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in 1X SSC, 0.1% SDS at 65°C and two washes of 30 minutes each in 0.2X SSC, 0.1% SDS at 65°C. In other embodiments, variants of the recited polynucleotides and/or polypeptides may be isolated from mycobacterial species. In certain preferred embodiments, variants of the recited polypeptides possess similar activity to the recited polypeptides as determined, for example, by their ability to stimulate cell proliferation and/or the production of cytokines or interferon- γ in human PBMC, measured as described in detail below.

A polypeptide of the present invention may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

As used herein, the term "x-mer," with reference to a specific value of "x," refers to a polynucleotide comprising at least a specified number ("x") of contiguous residues of any of the polynucleotides identified as SEQ ID NO: 5-21. The value of x may be from about 20 to about 600, depending upon the specific sequence.

Polynucleotides of the present invention comprehend polynucleotides comprising at least a specified number of contiguous residues (x-mers) of any of the polynucleotides identified as SEQ ID NO: 5-21 or their variants. According to preferred embodiments, the value of x is

preferably at least 20, more preferably at least 40, more preferably yet at least 60, and most preferably at least 80. Thus, polynucleotides of the present invention include polynucleotides comprising a 20-mer, a 40-mer, a 60-mer, an 80-mer, a 100-mer, a 120-mer, a 150-mer, a 180-mer, a 220-mer a 250-mer, or a 300-mer, 400-mer, 500-mer or 600-mer of a polynucleotide 5 identified as SEQ ID NO: 5-21 or a variant of one of the polynucleotides identified as SEQ ID NO: 5-21.

In general, the inventive polypeptides and polynucleotides, may be prepared using any of a variety of procedures. For example, polypeptides may be produced recombinantly by inserting a polynucleotide that encodes the polypeptide into an expression vector and expressing the 10 polypeptide in an appropriate host. Any of a variety of expression vectors known to those of ordinary skill in the art may be employed. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a polynucleotide that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are *E. coli*, mycobacteria, 15 insect, yeast or a mammalian cell line such as COS or CHO. The polynucleotides expressed in this manner may encode naturally occurring antigens, portions of naturally occurring antigens, or other variants thereof.

Polynucleotides of the present invention may be isolated by screening a *M. vaccae* genomic DNA library as described below in Example 1. Alternatively, polynucleotides encoding 20 *M. vaccae* epitopes may be obtained by screening an appropriate *M. vaccae* cDNA or genomic DNA library for DNA sequences that hybridize to degenerate oligonucleotides derived from amino acid sequences of isolated epitopes. Suitable degenerate oligonucleotides may be designed and synthesized, and the screen may be performed as described, for example in Sambrook *et al.* *Molecular cloning: a laboratory manual*. CSHL Press: Cold Spring Harbor, 25 NY, 1989. Polymerase chain reaction (PCR) may be employed to isolate a nucleic acid probe from genomic DNA, or a cDNA or genomic DNA library, using techniques well known in the art. The library screen may then be performed using the isolated probe.

Regardless of the method of preparation, the epitopes described herein have the ability to induce an immunogenic response. More specifically, as discussed above, the epitopes have the 30 ability to induce cell proliferation and/or cytokine production (for example, interferon- γ and/or

interleukin-12 production) in T cells, NK cells, B cells or macrophages derived from a mycobacteria-immune individual.

The selection of cell type for use in evaluating an immunogenic response to an epitope will depend on the desired response. For example, interleukin-12 production is most readily evaluated using preparations containing T cells, NK cells, B cells and/or macrophages derived from mycobacteria-immune individuals may be prepared using methods well known in the art. For example, a preparation of peripheral blood mononuclear cells (PBMCs) may be employed without further separation of component cells. PBMCs may be prepared, for example, using density centrifugation through Ficoll™ (Winthrop Laboratories, NY). T cells for use in the assays described herein may be purified directly from PBMCs. Alternatively, an enriched T cell line reactive against mycobacterial proteins, or T cell clones reactive to individual mycobacterial proteins, may be employed. Such T cell clones may be generated by, for example, culturing PBMCs from mycobacteria-immune individuals with mycobacterial proteins for a period of 2-4 weeks. This allows expansion of only the mycobacterial protein-specific T cells, resulting in a line composed solely of such cells. These cells may then be cloned and tested with individual proteins, using methods well known in the art, to more accurately define individual T cell specificity. Assays for cell proliferation or cytokine production in T cells, NK cells, B cells or macrophages may be performed, for example, using the procedures described below.

Among the immunogenic epitopes, polypeptides and/or polynucleotides of the present invention, those having superior therapeutic properties may be distinguished based on the magnitude of the responses in the above assays and based on the percentage of individuals for which a response is observed. In addition, epitopes having superior therapeutic properties will not stimulate cell proliferation or cytokine production *in vitro* in cells derived from more than about 25% of individuals that are not mycobacteria-immune, thereby eliminating responses that are not specifically due to mycobacteria-responsive cells. Thus, those antigens that induce a response in a high percentage of T cell, NK cell, B cell or macrophage preparations from mycobacteria-immune individuals (with a low incidence of responses in cell preparations from other individuals) have superior therapeutic properties.

Epitopes with superior therapeutic properties may also be identified based on their ability to diminish the severity of *M. tuberculosis* infection, or other mycobacterial infection, in

experimental animals, when administered as a vaccine. Suitable vaccine preparations for use in experimental animals are described in detail below.

Portions and other variants of the inventive polypeptides may be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and 5 generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. *See* Merrifield, *J. Am. Chem. Soc.* 85:2149-2154, 1963. Equipment for automated synthesis of 10 polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems, Inc. (Foster City, CA), and may be operated according to the manufacturer's instructions. Variants of a native epitope may be prepared using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis. Sections of the DNA sequence may also be removed using standard techniques to permit preparation of truncated 15 polypeptides.

The present invention also provides fusion proteins comprising a first and a second inventive polypeptide or, alternatively, a polypeptide of the present invention and a known *M. tuberculosis* antigen, such as the 38 kDa antigen described in Andersen and Hansen, *Infect. Immun.* 57:2481-2488, 1989, together with variants of such fusion proteins. In a related aspect, 20 DNA constructs comprising a first and a second inventive polynucleotide are also provided. Preparation of a construct comprising multiple epitopes of the present invention and expression of the corresponding recombinant protein is detailed below in Example 4. In general, a polynucleotide encoding a fusion protein of the present invention is constructed using known recombinant DNA techniques to assemble separate DNA sequences encoding the first and 25 second polypeptides into an appropriate expression vector. The 3' end of a DNA sequence encoding the first polypeptide is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide so that the reading frames of the sequences are in phase to permit mRNA translation of the two DNA sequences into a single fusion protein that retains the biological activity of both the first and the second polypeptides.

A peptide linker sequence may be employed to separate the first and the second polypeptides by a distance sufficient to ensure that each polypeptide fold into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen 5 based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in 10 the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea *et al.*, *Gene* 40:39-46, 1985; Murphy *et al.*, *Proc. Natl. Acad. Sci. USA* 83:8258-8262, 1986; and U.S. Patent Nos. 4,935,233 and 4,751,180. The linker sequence may be from 1 to about 50 amino acids in length. Peptide linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that 15 can be used to separate the functional domains and prevent steric interference. The ligated DNA sequences encoding the fusion proteins are cloned into suitable expression systems using techniques known to those of ordinary skill in the art.

In another aspect, the present invention provides methods for using one or more of the inventive polypeptides or fusion proteins (or polynucleotides encoding such polypeptides or 20 fusion proteins) to induce protective immunity against disorders such as tuberculosis in a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may be afflicted with a disease, or may be free of detectable disease or infection. In other words, protective immunity may be induced to prevent or treat disorders.

In related aspects, the *M. vaccae* polynucleotides and polypeptides of the present 25 invention may be employed to activate T cells and NK cells; to stimulate the production of cytokines (in particular Th1 class of cytokines) in human PBMC; to produce anti-epitope antibodies; and/or to induce long-term memory cells.

For use in such methods, the polypeptide, fusion protein or polynucleotide is generally 30 present within a pharmaceutical composition or a vaccine. Pharmaceutical compositions may comprise one or more polypeptides, each of which may contain one or more of the above

sequences (or variants thereof), and a physiologically acceptable carrier. Vaccines may comprise one or more of the above polypeptides and an immunostimulant, such as an adjuvant or a liposome, into which the polypeptide is incorporated. Such pharmaceutical compositions and vaccines may also contain other mycobacterial antigens, either incorporated into a fusion protein or present within a separate polypeptide.

5 Alternatively, a vaccine of the present invention may contain a polynucleotide encoding one or more polypeptides as described above, such that the polypeptide is generated *in situ*. In such vaccines, the polynucleotide may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacterial 10 and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA/RNA sequences for expression in the patient (such as a suitable promoter and terminator signal). Bacterial delivery systems involve the administration of a bacterium (such as *Bacillus Calmette-Guerin*) that expresses an immunogenic epitope of the polypeptide on its cell surface. In a preferred embodiment, the DNA and/or RNA may be introduced using a viral expression 15 system (e.g., *vaccinia* or other poxvirus, retrovirus, or adenovirus), that may involve the use of a non-pathogenic, or defective, replication competent virus. Techniques for incorporating DNA and/or RNA into such expression systems are well known in the art. The DNA may also be "naked," as described, for example, in Ulmer et al., *Science* 259:1745-1749, 1993 and reviewed by Cohen, *Science* 259:1691-1692, 1993. The uptake of naked DNA may be increased by 20 coating the DNA onto biodegradable beads, which are efficiently transported into the cells. Methods for the administration of polynucleotide sequences comprising DNA and/or RNA include those disclosed in US Patent Nos. 5,580,859 and 5,589,466.

A polynucleotide vaccine as described above may be administered simultaneously with or sequentially to either a polypeptide of the present invention or a known mycobacterial antigen, 25 such as the 38 kDa antigen described above. For example, administration of DNA encoding a polypeptide of the present invention, may be followed by administration of an antigen in order to enhance the protective immune effect of the vaccine.

Routes and frequency of administration, as well as dosage, will vary from individual to individual and may parallel those currently being used in immunization using *M. bovis* BCG. In 30 general, the pharmaceutical compositions and vaccines may be administered by injection

(e.g., intradermal, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 3 doses may be administered for a 1-36 week period. Preferably, 5 3 doses are administered, at intervals of 3-4 months, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of polypeptide or polynucleotide that, when administered as described above, is capable of raising an immune response in a patient sufficient to protect the patient from mycobacterial infection for at least 1-2 years. In general, the amount of polypeptide present in a dose (or produced *in situ* by the polynucleotide in a dose) ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg, and preferably from about 10 100 pg to about 1 μ g. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 ml to about 5 ml.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the 15 carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactic galactide) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable 20 biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109.

Any of a variety of immunostimulants, such as an adjuvant, may be employed in the vaccines of this invention to non-specifically enhance the immune response. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum 25 hydroxide or mineral oil, and a non-specific stimulator of immune responses, such as lipid A, *Bordetella pertussis*, *M. tuberculosis*, or, as discussed below, *M. vaccae*. Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Freund's Complete Adjuvant (Difco Laboratories, Detroit, MI), and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ). Other suitable adjuvants include alum, biodegradable microspheres, 30 monophosphoryl lipid A and Quil A.

The following examples are offered by way of illustration and not by way of limitation.

EXAMPLE 1

CLONING AND SELECTION OF IMMUNOGENIC *M. VACCAE* EPITOPES

5

M. vaccae (ATCC Number 15483, Rockville, MD) was cultured in medium 90 (yeast extract, 2.5 g/l; tryptone, 5 g/l; glucose, 1 g/l) at 37 °C for four days. Genomic DNA was isolated from these cells following standard protocols and then digested with restriction endonuclease *Sau*3A under conditions that produced DNA fragments of approximately 0.25 kb.

10 The fragments were purified using the QIAquick PCR clean-up system (Qiagen, Venlo, The Netherlands).

To express the cloned *M. vaccae* DNA in three different reading frames, the pcDNA3 expression vector (Invitrogen, Carlsbad, CA) was modified by insertion of a human growth hormone signal peptide (to facilitate recombinant protein secretion) amplified with three 15 different 3' primers. These primers allowed the insertion of one or two extra base pairs into the PCR product to shift the reading frame of the expressed polypeptide. The primers were AD105 (human growth hormone 5' primer; SEQ ID NO: 1) and the three human growth hormone (hGH) 3' primers AD106, AD107 and AD108 (SEQ ID NO: 2-4, respectively). From these PCR fragments, most of the hGH sequence downstream of the leader sequence cleavage site was 20 removed by digestion with the restriction endonuclease *Bsg*II. The hGH PCR fragments were then cloned into the pcDNA3 expression vector following digestion with the restriction endonucleases *Hind*III and *Bam*HI. The nucleotide sequence of the inserted fragments are given in SEQ ID NO: 5-7, with the corresponding amino acid sequences being provided in SEQ ID NO: 61-63, respectively. Three expression libraries (one for each of the three reading frames) 25 were constructed by cloning the 0.25 kb *M. vaccae* PCR fragments, prepared as described above, into the *Bam*HI cloning site of the chimeric pcDNA3/human growth hormone vectors (pcDNA3-hGH1', pcDNA3-hGH2' and pcDNA3-hGH3'). Replica lift master plates were made of bacterial colonies transformed with the library constructs and stored. Plasmid DNA, prepared from these colonies, was divided into 500 pools, each containing DNA from 40 to 50 plasmids. 30 The DNA was transfected into COS7 cells using lipofectamine (BRL Life Technologies,

Gaithersburg MD) and the immunogenic properties of the products of each group were determined by a spleen cell assay, wherein the production of IFN- γ in cultures of spleen cells obtained from mice primed with heat-killed *M. vaccae* was determined by ELISA as described below.

5 Plasmid pools that encoded recombinant polypeptides eliciting an immune response (as determined by the ability to increase IFN- γ production in the spleen cell assay), were subdivided into smaller pools containing 10 plasmids each and these pools were again transfected into COS7 cells. The culture supernatants of these cells were subjected to the spleen cell assay as described above.

10 After three rounds of screening, 120 plasmids were identified that encoded recombinant polypeptides stimulating spleen cells of heat-killed *M. vaccae*-immunised mice to produce IFN- γ . The 120 supernatants of COS7 cells transfected with these plasmids were screened in two additional assays, namely the mouse memory assay and the human peripheral blood mononuclear cell (PBMC) assay. In the mouse long-term memory assay, mice were injected 15 with a sub-lethal dose of 10^4 colony forming units (CFU) of *M. tuberculosis*. After 4 weeks, the mice were treated with antibiotics for a further 4 weeks to cure them of *M. tuberculosis* infection, followed by a resting period of 4 weeks. A second injection of live *M. tuberculosis* (5×10^5 CFU) was given before the immunogenicity of the plasmid products was measured four days later using the spleen cell assay described above.

20 In the PBMC assay, the 120 supernatants of COS7 cells transfected with the plasmids were screened for the ability to induce T-cell proliferation and IFN- γ production in peripheral blood cells from mycobacteria-immune human donors. These donors were known to be PPD (purified protein derivative from *M. tuberculosis*) positive and their T cells were shown to proliferate and produce IFN- γ in response to PPD. Donor PBMCs and COS7 supernatants were 25 cultured in medium comprising RPMI 1640 supplemented with 10% (v/v) autologous serum, penicillin (60 μ g/ml), streptomycin (100 μ g/ml), and glutamine (2 mM). After 3 days, 50 μ l of medium was removed from each well for the determination of IFN- γ levels, as described below. The plates were cultured for a further 4 days and then pulsed with 1 μ Ci/well of tritiated thymidine for 18 hours, harvested and tritium uptake determined using a scintillation counter.

Supernatants that stimulated proliferation in two replicates at levels two-fold greater than the proliferation observed in cells cultured in medium alone were considered positive.

IFN- γ was measured using an enzyme-linked immunosorbent assay (ELISA) as follows. ELISA plates were coated with a mouse monoclonal antibody directed to human IFN- γ (Endogen, Woburn, MA) by incubating the wells with 1 μ g/ml antibody in phosphate-buffered saline (PBS) for 4 hours at 4°C. Wells were blocked with PBS containing 0.2% Tween 20 for 1 hour at room temperature. The plates were then washed four times in PBS/0.2% Tween 20, and samples diluted 1:2 in culture medium in the ELISA plates were incubated overnight at room temperature. The plates were again washed, and a biotinylated polyclonal rabbit anti-human IFN- γ serum (Endogen), diluted to 1 μ g/ml in PBS, was added to each well. The plates were then incubated for 1 hour at room temperature, washed, and horseradish peroxidase-coupled avidin A (Vector Laboratories, Burlingame, CA) was added at a 1:4,000 dilution in PBS. After a further 1 hour incubation at room temperature, the plates were washed and orthophenylenediamine (OPD) substrate added. The reaction was stopped after 10 minutes with 10% (v/v) HCl. The optical density (OD) was determined at 490 nm. Supernatants that resulted in both replicates giving an OD two-fold greater than the mean OD from cells cultured in medium alone were considered positive.

From the results of these two assays, 59 plasmids were identified that encoded recombinant polypeptides containing immunogenic determinants, or epitopes. These epitopes were found to elicit an immune response in mice and humans, and are cross-reactive with *M. tuberculosis* immunogenic determinants inducing long term responses. These plasmids were tested for their ability to induce protective immunity in the mouse model of tuberculosis as follows. Each plasmid (100 μ g of DNA) was injected IM in the tibialis anterior of anaesthetised mice, three times every three weeks. After nine weeks, the mice were challenged with *M. tuberculosis* (5×10^5 CFU). Organ homogenates from lungs and spleens were prepared in week 12 and plated out on 7H9 medium supplemented with oleic acid-albumin-dextrose-catalase (OADC) to determine the number of CFU present in each homogenate. Results were recorded after a two-week incubation period.

Using the protocols described above, eight plasmids containing immunogenic epitopes were selected. After identification of the putative open reading frames (ORFs) in these

constructs, the *M. vaccae* fragments comprising only the ORF-portion were sub-cloned into pcDNA3-hGH' as described above. These plasmids were called DNA5, DNA9, DNA26, DNA27, DNA29, DNA37, DNA44 and DNA45. Three ORFs, referred to as A, B and C, were identified in DNA9. Open reading frames B and C were in the reverse orientation and were 5 discarded. ORF A was cloned separately and the resulting plasmid was called DNA9A. The determined genomic DNA sequences of the inserts of DNA5, DNA9A, DNA26, DNA27, DNA29, DNA37, DNA42, DNA44 and DNA45 are given in SEQ ID NO: 13-21, respectively, with the predicted amino acid sequences of the corresponding ORFs being provided in SEQ ID NO: 69-77, respectively. More than one epitope was identified in the inserts of the plasmids 10 DNA5 and DNA27. These epitopes were not separated by cloning and were tested as multiple epitopes in all the assays. The determined genomic DNA sequences of epitope 1, epitope 2 and epitope 3 of DNA5, and of epitope 1 and epitope 2 of DNA27 are given in SEQ ID NO: 8-12, respectively, with the corresponding predicted amino acid sequences being provided in SEQ ID NO: 64-68, respectively. The determined epitope DNA sequences were compared to sequences 15 in the EMBL DNA database using the FASTA computer algorithm. The corresponding predicted protein sequences (DNA translated to protein in each of 6 reading frames) were compared to sequences in the SwissProt database using the computer algorithm FASTX. Comparisons of DNA sequences provided in SEQ ID NO: 8-21 to sequences in the EMBL DNA database (using FASTA) and amino acid sequences provided in SEQ ID NO: 64-77 to sequences 20 in the SwissProt database (using FASTX) were made as of March 21, 1999.

The predicted amino acid sequences of DNA5 epitope 2, DNA27 epitope 1, DNA9A, DNA29, DNA37, DNA44 and DNA45 (provided in SEQ ID NO: 65, 67, 70, 73, 74, 76 and 77, respectively) were found to have less than 50% identity, determined as described above, to sequences in the SwissProt database using FASTX. The predicted amino acid sequences of 25 DNA5 epitopes 1 and 3 (provided in SEQ ID NO: 64 and 66, respectively) were found to have less than 75% identity, determined as described above, to sequences in the SwissProt database using FASTX. No matches were found to the predicted amino acid sequence of DNA27 epitope 2 and DNA26 (provided in SEQ ID NO: 68 and 71, respectively). Table 1, below, shows the results of the comparison of the inventive amino acid sequences with those in the SwissProt

database using FASTX as described above, wherein "No. of identical residues" represents the number of identical residues within the aligned portion.

TABLE 1

5

	SEQ ID NO:	Length (residues)	Length of alignment (residues)	No. of identical residues	% of identical residues
DNA5, epitope 1	64	13	11	8	61
DNA5, epitope2	65	32	31	10	32
DNA5, epitope 3	66	26	25	14	53
DNA9A	70	75	68	24	32
DNA26	71	97	No Hits		
DNA27, epitope 1	67	38	30	16	42
DNA27, epitope 2	68	11	No Hits		
DNA29	73	46	40	17	37
DNA37	74	87	80	26	32
DNA44	76	44	35	17	38
DNA45	77	59	52	21	35

EXAMPLE 2

10

EXPRESSION OF RECOMBINANT EPITOPEs IN PROKARYOTIC AND EUKARYOTIC CELLS

Epitope DNA was subcloned into vectors for expression of polypeptides in bacterial and eukaryotic cells. The bacterial expression vector was a modified pET16 vector (Novagen, 15 Madison, WI). Inserts from all the plasmids except for DNA9, were amplified with primers AD136 and AD133 (SEQ ID NO: 22 and 23, respectively) and cloned by blunt-end ligation into the pET16 vector that was *Eco*RI-digested and end-filled with DNA polymerase *Pfu*I (Stratagene, La Jolla CA). The insert of DNA9A was amplified with AD250 and AD251 (SEQ ID NO: 24 and 25, respectively) and cloned into the pET16 vector as described above.

20

To express the polypeptides in eukaryotic cells, the pcDNA3 vector (Invitrogen) was modified to include a histidine tag at the 3' end of the cloning site. This was done by cloning the

double-stranded oligonucleotide AD180/AD181 into pcDNA3 digested with *Bam*HI and *Eco*RI. The sequences of oligonucleotides AD180 and AD181 are given in SEQ ID NO: 26 and 27, respectively. Plasmid inserts were amplified with the hGH-specific N-terminus 5' primer AD134 (SEQ ID NO: 28) and an epitope-specific 3' end primer, using the pcDNA3-hGH' constructs as DNA template. The sequences of the epitope-specific 3' primers AD151 (DNA5), AD153 (DNA26), AD154 (DNA27), AD155 (DNA29), AD158 (DNA42), AD159 (DNA44), AD160 (DNA45), AD167 (DNA37) and AD182 (DNA9) are listed in SEQ ID NO: 29-37, respectively.

This vector was again modified to remove excess sequence (42 nucleotides) between the hGH leader sequence and the expressed sequence, so that the hGH' sequence in this construct was reduced to the leader sequence and the first 5 N-terminal amino acids of the hGH sequence only. Using the pcDNA3-hGH3' construct as DNA template, the shortened fusion partner was amplified by PCR using primers AD105 (SEQ ID NO: 1) and AD222 (SEQ ID NO: 38). Cloning into pcDNA3-His was done at the *Hind*III and *Bam*HI sites and the resulting construct was called pcDNA3-hGHls/His. The determined DNA sequence of the hGH-fusion partner cloned into pcDNA3-hGH-ls is given in SEQ ID NO: 39 and the corresponding amino acid sequence in SEQ ID NO: 78. The construct consisting of the insert from DNA9A was prepared by PCR amplification using primers AD223 and AD226 (SEQ ID NO: 40 and 41, respectively).

20

EXAMPLE 3

IMMUNOGENICITY OF RECOMBINANT EPITOPE CONSTRUCTS

This example describes the results of immunogenicity studies performed with eight selected recombinant epitopes in either DNA or recombinant polypeptide form.

25

A. Stimulation of Human Peripheral Blood Mononuclear Cells (PBMC) to proliferate and secrete Interferon gamma (IFN- γ) *in vitro*

The recombinant epitopes (1 and 10 μ g) expressed by the pET16 bacterial expression system were cultured with human PBMC at 37 °C. After 48 hours, IFN- γ secretion was measured by enzyme-linked immunoassay (ELISA) following standard procedures. Parallel

cultures were pulsed with tritiated thymidine and DNA synthesis was used to assess PBMC proliferation. For comparison, cells were also cultured with Purified Protein Derivative (PPD) from *M. tuberculosis* and with PBS as a negative control.

As shown in Table 2, all recombinant epitopes have the ability to stimulate IFN- γ production in at least some PBMC samples. Of the 12 PBMC samples tested, 10 were PPD positive, i.e., the PBMCs from these samples produced IFN- γ when cultured with PPD, and 2 were PPD-negative. PBMC responses were considered positive when the amount of IFN- γ produced was at least 3-fold higher than the IFN- γ produced by the PBS control samples. Recombinant epitopes 5 (corresponding to DNA5) and 44 (corresponding to DNA44) stimulated IFN- γ production in 100% of the PPD⁺ samples. Recombinant epitope 27 (corresponding to DNA27) stimulated IFN- γ production in 80% of the PPD⁺ samples. Recombinant epitopes 26 and 37 (corresponding to DNA26 and DNA37, respectively) stimulated IFN- γ production in 70% of the PPD⁺ samples, whereas epitope 45 (corresponding to DNA45) stimulated 20% PPD⁺ of the PBMC samples. PBMCs from PPD⁻ samples did not respond significantly to any of the recombinant epitopes. This demonstrates that the epitopes are immunogenic in humans and trigger a recall response in samples from donors that were previously exposed to mycobacteria.

TABLE 2
Stimulation of IFN- γ production in human PBMC by recombinant epitopes

20

Human PBMC	PBS control	PPD control	Recombinant Epitopes					
			26	37	44	45	5	27
G97022	<0.1	0.16	0.3	0.3	0.4	<0.1	0.5	0.1
G97037	<0.1	0.3	0.3	0.3	0.8	0.2	0.3	0.3
G97001	<0.1	4.5	0.6	1	3.5	0.2	1.8	1.7
G97008	<0.1	4.4	0.16	0.5	4	<0.1	0.73	0.9
G97011	0.25	4.9	0.9	0.5	1.2	0.25	2.8	1.2
G97030	<0.1	1.8	0.5	0.2	3.5	0.1	1.8	3
G97033	0.12	4.5	0.5	0.25	3.4	0.2	1.7	1

G97010	<0.1	>4	>4	>4	>4	1	>4	>4
G97028	<0.1	>4	>4	>4	>4	1.2	>4	>4
G97020	<0.1	1	0.3	0.25	>4	<0.1	1.5	0.5
G97032	<0.1	>4	0.5	1.2	>4	<0.1	1.4	0.5
G97035	<0.1	3.5	0.4	3.5	>4	<0.1	1	1

* Results are expressed as IFN- γ in ng/ml

5 Immunogenicity of the epitopes in humans was further demonstrated by the proliferative response of the human PBMC samples to both PPD and recombinant epitopes. The ability of the recombinant epitopes to stimulate PBMC proliferation was expressed as a stimulation index. A proliferation stimulus is considered positive when it is 5 times greater than the mean background proliferation produced by the medium-only control. As shown in Table 3, all recombinant epitopes were found to have the ability to stimulate PBMC proliferation in at least some of the 10 human PBMC samples. Recombinant epitopes 26 and 27 stimulated PBMC proliferation in 92% of the samples, while recombinant epitopes 5, 37 and 44 stimulated proliferation in 83% of the samples. Epitope 45 stimulated PBMC proliferation in 17% of the samples. Stimulation of PBMC by PPD was 83%.

15

TABLE 3
Stimulation of PMBC proliferation

Human PBMC	Recombinant epitopes						
	PPD	5	26	27	37	44	45
G97022	5*	12	14	3	20	20	1
G97037	35	12	25	20	15	30	1
G97001	5	6	6	5	8	7	1
G97008	60	20	30	15	40	60	2
G97011	40	33	30	27	30	30	3

G97030	100	140	120	140	120	140	30
G97033	20	12	12	11	10	15	1
G97010	2	4	2	6	2	4	2
G97028	60	48	60	40	55	52	12
G97020	10	10	10	8	10	10	1
G97032	45	30	35	33	38	42	2
G97035	3	4	5	6	3	4	2

* Results of human PBMC proliferation are expressed as Stimulation Index.

B. Immunization of mice with DNA epitopes

5 Protective immunity against subsequent infection with *M. tuberculosis* was induced in BALB/cByJ mice after injection of DNA encoding eight of the recombinant epitopes in pcDNA-hGH'/His or pcDNA3-hGHs/His constructs.

10 Induction of protective immunity was considered positive when a mean 0.5 log reduction in CFU in lung homogenates, compared to the mean CFUs from non-immunised control mice, was observed following subsequent infection with *M. tuberculosis*. A plasmid without an insert 15 was used as control. The reduction in CFUs after epitope DNA immunisation was also compared with the known immunogenicity of *M. bovis* BCG. The results clearly show a reduction in CFUs in all the mice tested, suggesting the induction of protective immunity by the recombinant epitope DNA. In six of the groups, the reduction in CFUs was greater than 50% and in three of the groups the reduction was comparable to that induced by injection with *M. bovis* BCG.

TABLE 4

Protective immunity in mice induced by genetic immunisation with eight pcDNA-hGH'/His and pcDNA3-hGHls/His constructs

Epitope construct	SEQ ID NO:	Number of Mice	Number of mice with reduced CFUs	% Mice with Reduced CFUs
Control plasmid		14	2	14
DNA5	13	11	4	36
DNA9	14	13	7	55
DNA26	15	10	7	70
DNA27	16	13	7	55
DNA29	17	13	7	55
DNA37	18	13	8	62
DNA44	20	13	6	46
DNA45	21	13	8	62
M. bovis BCG		23	17	74

5

The induction of cytotoxic T lymphocytes (CTL), cytokines (IFN- γ , IL-4, IL-6 and IL-10), and proliferative and antibody responses upon genetic immunisation with eight pcDNA-hGH'/His or pcDNA3-hGHls/His constructs were assessed as follows.

10 **CTL assay:**

Cytolytic (CTL) activity in spleen cells of DNA-immunised BALB/cByJ mice was measured following a standard two-step procedure using the MHC haplotype matching target cells, BALB-3T3 (ATCC No. CRL-163, American Type Culture Collection, Manassas, VA).

15 Target cells were prepared by transfecting BALB/3T3 cells with eight pcDNA-hGH'/His or pcDNA3-hGHls/His epitope DNA constructs. Stably transfected cell lines were produced by geneticin selection (G418; Gibco BRL Life Technologies) and single cells were isolated by limiting dilution. Clones expressing epitopes were selected by RT-PCR using primers AD105 and AD181 (SEQ ID NO: 1 and 27, respectively). Spleen cells of DNA-immunised mice were

cultured in cDMEM enriched with 10% FCS in the presence of mytomycin-treated BALB-3T3 cells transfected with matching epitope DNA to re-stimulate cytotoxic T cells *in vitro*. Cultures were incubated at 37 °C under 10% CO₂ for 6 days. Cytolytic activities were monitored by incubating a fraction of each stimulated cell culture with DNA-matched target cells that were 5 pulsed with ⁵¹Chromium, and measuring ⁵¹Chromium release in the supernatant of cell cultures. As shown in Table 5, specific CTL activity was detected in the spleens of mice immunised with four of the DNA constructs tested.

Cytokine and proliferative responses:

10 Cytokine production and proliferative responses of spleen cells from DNA-immunised BALB/cByJ mice were assessed following *in vitro* re-stimulation with recombinant epitopes. Cytokine and proliferative responses were measured by ELISA and 3H-thymidine pulse, respectively, as described above. As shown in Table 5, spleen cells from the six groups tested produced the Th1 cytokine IFN- γ . No Th2 cytokines (e.g. IL-4, IL-6 and IL-10) were detected in 15 supernatants of stimulated cells. Proliferative responses were low and detected in spleen cells from two immunised groups only.

Antibody responses

20 Blood samples from three DNA-immunised BALB/cByJ mice were collected two weeks after the last DNA injection and sera were prepared according to standard procedures. The presence of anti-epitope antibodies was determined by ELISA. The wells of a microtitre plate were coated with 500 ng of recombinant epitope. Antibody titres were measured by adding serial dilutions of serum into the wells. Bound antibodies were detected according to ELISA 25 procedures as described above. As shown in Table 5, anti-epitope antibodies were detected in two blood samples tested. ELISA assays were also performed to determine whether the antibodies belonged to the IgG1 or IgG2a subclasses, using standard protocols. The results showed that the antibodies belonged to the IgG2a subclass, which is characteristic of a Th1 antibody response.

The data summarised in Table 5 indicate that immunisation with epitope DNA induced an immune response in mice. Furthermore, the cellular and humoral responses detected in the DNA-immunised mice demonstrated that a Th1 response was generated.

5

TABLE 5

Cytotoxic lymphocyte induction, cytokine responses, proliferation and antibody production induced in mice by genetic immunisation with eight pcDNA-hGH'/His or pcDNA3-hGHls/His constructs.

Epitope constructs	SEQ ID NO:	CTL induction (% Specific lysis)*	Cytokine responses (IFN- γ in ng/ml)**	Proliferation (Stimulation Index)	Antibodies (titer)
DNA5	13	30	15	not detected	not detected
DNA9A	14	10	NT***	NT	NT
DNA26	15	not detected	30	7	not detected
DNA27	16	not detected	33	3	1/100
DNA29	17	not detected	NT	NT	NT
DNA37	18	not detected	18	not detected	not detected
DNA44	20	25	23	not detected	1/100
DNA45	21	20	12	not detected	not detected

10

* Data shown is the mean % lysis from spleen cells of three mice. Non-specific lysis of control cells was deducted.

** Data shown is the mean IFN- γ in ng/ml obtained from triplicates of spleen cell cultures from three mice. Background IFN- γ produced by control cells was 5-7 ng/ml.

15

*** NT=Not Tested

EXAMPLE 4

CLONING STRATEGY FOR *M. VACCAE* MULTI-EPITOPE CONSTRUCTS

20

The eight epitopes assayed in Example 4 were assembled to form multi-epitope constructs. Specifically, the DNA was amplified with primers containing a *Bgl*II 5'-extension and *Bam*HI 3'-extension and was sequentially cloned into the *Bam*HI site of pcDNA3/hGHls/His. The primers were AD223, AD226, AD229, AD230, AD231, AD232,

AD233, AD234, AD235, AD236, AD256, AD258, AD259, AD260, AD261 and AD262 (SEQ ID NO: 40-55, respectively).

The insert of plasmid DNA9A was cloned first into the *Bam*HI site of pcDNA3-hGHls/His. The *Bam*HI site of the vector was reconstituted at the 3' end of the cloning junction 5 only and all other inserts except DNA5 were sequentially cloned into the same site. The insert of plasmid DNA5 was cloned last by blunt ligation into the end-filled *Bam*HI site of pcDNA3-hGHls/His. Following this protocol, various combinations of epitopes were cloned into the pcDNA3-hGHls/His vector. The determined DNA sequences of three multi-epitope constructs consisting of 8-mer multi-epitopes (called ME/A, ME/B and ME/D) are shown in SEQ ID 10 NO: 56-58, respectively, and the predicted corresponding amino acid sequences in SEQ ID NO: 79-81, respectively. Each one of these multi-epitope constructs includes each one of the 8 epitopes, but in a different order.

For expression of multi-epitope recombinant proteins in bacteria, the inserts of plasmids ME/A, ME/B and ME/D were subcloned into the modified expression vector pET16. All 8-mer 15 epitope DNA combinations had DNA9A and DNA5 at the 5' and 3' end, respectively. The plasmid inserts were amplified using primers AD272 and AD273 (SEQ ID NO: 59 and 60, respectively) and the purified amplified fragments cloned by blunt-end ligation into the pET16 vector that was *Eco*RI-digested and end-filled with DNA polymerase *Pfu*I (Stratagene). Recombinant protein was expressed using *E. coli* host cells according to the manufacturer's 20 protocol and purified using standard protocols.

EXAMPLE 5

IMMUNIZATION OF MICE WITH *M. VACCAE* MULTI-EPITOPE CONSTRUCTS

25 This example illustrates the protective immunity against subsequent infection with *M. tuberculosis* in BALB/cByJ mice after injection of multi-epitope constructs in either DNA or recombinant polypeptide form.

BALB/cByJ mice were divided into three groups of six mice that received different 30 treatments. Mice in Group 1 were immunized intraperitoneally with one dose of 500 µg *M. bovis* BCG or PBS. Group 2 mice were immunized three times intramuscularly in the *tibialis*

anterior with 100 µg ME/D DNA or empty vector DNA at three week intervals. Mice in Group 3 were immunized intraperitoneally at three week intervals with either 1 or 2 doses of 50 µg recombinant ME/D in IFA, or 50 µg control protein in IFA. The control protein GV14B consisted of a non-naturally occurring protein derived from DNA encoding the *M. vaccae*-homologue of mycobacterial Elongation factor G and cloned into pET16g3 in reverse orientation.

Three weeks after the last immunization, the mice were challenged with live *M. tuberculosis* (5 X 10⁵ CFU). Organ homogenates from lungs and spleens were prepared after a further three weeks and plated out on 7H9 medium supplemented with oleic acid-albumin-dextrose-catalase (OADC) to determine the number of CFU present in each homogenate. Results were recorded after a two-week incubation period.

Induction of protective immunity was considered positive when a mean 0.5 log reduction in CFU in lung and spleen homogenates, compared to the mean CFUs from non-immunized control mice, was observed following subsequent infection with *M. tuberculosis*. The reduction in CFUs after immunization with ME/D DNA or recombinant ME/D polypeptide was compared with the known immunogenicity of *M. bovis* BCG. The results (Fig. 1) show a reduction in CFUs in the lungs and spleens from mice immunized with the ME/D DNA as well as the recombinant ME/D construct. The protective immunity of the ME/D DNA and the rME/D polypeptide demonstrated by the reduction in both lung and spleen CFUs was greater than the reduction in lung CFU after immunization with single epitope constructs (Table 4).

EXAMPLE 6

IMMUNOGENICITY OF *M. VACCAE* MULTI-EPITOPE CONSTRUCTS

This example describes the results of immunogenicity studies performed with three multi-epitope constructs in either DNA or recombinant polypeptide form.

A. Recombinant multi-epitope constructs ME/A, ME/B and ME/D stimulate mouse lymph node cells to proliferate and secrete IFN- γ *in vitro*

The recombinant multi-epitope constructs rME/A, rME/B and rME/D were screened for their ability to induce T-cell proliferation and IFN- γ in murine lymph node cells. For this assay,

BALB/cByJ mice were immunized subcutaneously in each footpad with 10 µg of the recombinant multi-epitope constructs rME/A, rME/B or rME/C diluted in an equal volume of IFA. Mice from the control group received PBS in IFA. Mice were sacrificed after nine days and the lymph nodes removed. Lymph node cells were cultured in medium comprising DMEM 5 supplemented with 10% (v/v) autologous serum, penicillin (60 µg/ml), streptomycin (100 µg/ml), and glutamine (2 mM) in the presence of 0, 0.125, 0.25 or 0.5 µM rME/A, rME/B or rME/D, as well as the control protein GV14B. After 3 days, 50 µl of medium was removed from each well for the determination of IFN-γ levels, as described above. The plates were cultured for a further 4 days and then pulsed with 1 µCi/well of tritiated thymidine for 18 hours. Cells were 10 harvested and tritium uptake determined using a scintillation counter. Supernatants that stimulated proliferation in two replicates at levels two-fold greater than the proliferation observed in cells cultured in medium alone were considered positive.

Results from the murine proliferation experiments are shown in Figs. 2A-D. All three of the recombinant multi-epitope constructs induced a proliferative response in lymph node cells 15 from immunized mice. The levels of proliferation induced by the three recombinant multi-epitope constructs rME/A, rME/B and rME/D (Fig. 2A, B and C, respectively) were similar, showing that the constructs were antigenically identical. No proliferation was obtained from control mice immunized with PBS (Fig. 2D).

The levels of IFN-γ secreted by stimulated lymph node cells from mice immunized with 20 rME/A, rME/B or rME/D are shown in Fig. 3A-C, respectively. All three recombinant multi-epitope constructs stimulated IFN-γ secretion by lymph node cells, with the highest levels stimulated with rME/B (Fig. 3B). Cells from control mice stimulated with PBS secreted undetectable amounts of IFN-γ (Fig. 3D). These results suggested that immunization with the multi-epitope constructs induced a Th1 immune response in the mice.

25

B. Recombinant multi-epitope construct ME/D and ME/D DNA stimulate lymph node and spleen cells from mice immunized by different routes to proliferate and secrete IFN-γ *in vitro*

In these experiments, lymph node or spleen cells from mice immunized subcutaneously, 30 intraperitoneally or intramuscularly with the recombinant multi-epitope construct rME/D or the

DNA form of the multi-epitope construct ME/D were stimulated to induce T-cell proliferation and IFN- γ production. BALB/cByJ mice were immunized either subcutaneously in each footpad with one dose of 10 μ g rME/D in IFA, intraperitoneally with one dose of 50 μ g rME/D in IFA, or intramuscularly with three doses at 3 week intervals with 100 μ g ME/D DNA. Control mice 5 were immunized with PBS by the three different immunization routes. After nine days, mice immunized by the subcutaneous and intraperitoneal routes were sacrificed and the lymph nodes (subcutaneous immunization) or spleen cells (intraperitoneal immunization) removed. Spleen cells from mice immunized by intramuscular injection were harvested 15 days after the last immunization. Proliferation and IFN- γ production by these cells were determined as described 10 above.

Results from these experiments are presented in Fig. 4 and Fig. 5. In Fig. 4A, specific proliferative responses by lymph node and spleen cells from mice immunized with rME/D or ME/D DNA are shown. In comparison, Fig. 4B shows the low proliferation by cells from control mice. Similarly, lymph node and spleen cells from mice immunized with rME/D or 15 ME/D DNA were stimulated to secrete IFN- γ (Fig. 5A) while low levels of IFN- γ was secreted by lymph node and spleen cells from control mice immunized with PBS.

C. Single epitopes from multi-epitope constructs stimulate lymph node and spleen cells from mice immunized with recombinant multi-epitope construct rME/D or ME/D DNA by 20 different routes to proliferate and secrete IFN- γ *in vitro*

In these experiments, lymph node and spleen cells from mice immunized with the recombinant multi-epitope construct rME/D or the DNA form of the multi-epitope construct ME/D by different immunization routes were re-stimulated with the recombinant form of the single epitopes DNA5, DNA9, DNA26, DNA27, DNA29, DNA37, DNA44 and DNA45. The 25 experimental procedure was the same as outlined above. Results from these experiments are shown in Fig. 6A-B and Fig. 7A-B. Specific proliferative responses and IFN- γ secretion were detected in cells re-stimulated with epitopes DNA5, DNA9A, DNA26, DNA37 and DNA44 (Fig. 6A and Fig. 7A). Proliferation and IFN- γ production by epitopes DNA27, DNA29 and DNA45 were shown in at least one immunization group. Low levels of proliferation and IFN- γ 30 production was observed in cells from control mice immunized with PBS (Fig. 6B and Fig. 7B).

The data indicates that the epitopes are all individually antigenic when presented to the immune system as part of a multi-component immunogen.

D. Cytokine production

The cytokine production by spleen cells from mice immunized with the DNA form of the multi-epitope construct ME/D and re-stimulated with rME/A or rME/D was determined as follows. BALB/cByJ mice were immunized intramuscularly with three doses at three week intervals of 100 µg ME/D DNA. Fifteen days after the last injection, mice were sacrificed and the spleen cells removed. The spleen cells were re-stimulated with rME/A, rME/D or the control protein GV14B and the supernatants screened for cytokine production following standard procedures. Cytokine production by the spleen cells is given in Table 6.

TABLE 6

Cytokines secreted by splenocytes from BALB/cByJ mice immunized with ME DNA

Plasmid	IL-2*			IL-4*			IL-6*		
	rME/A	rME/D	GV14B	rME/A	rME/D	GV14B	rME/A	rME/D	GV14B
ME/A	122	125	<50	42	56	39	147	196	<30
ME/B	267	200	<50	20	<10	<10	79	56	<30
ME/D	96	77	<50	13	<10	<10	131	98	<30
Control	<50	<50	<50	<10	<10	<10	<30	<30	<30

*Cytokine concentration measured in pg/ml, with a standard error of <10%

As shown in Table 6, IL-2 and IL-6 were secreted by spleen cells of mice stimulated with rME/A and rME/D. IL-2 is a cytokine secreted during a Th1-type immune response, providing further evidence that the multi-epitope constructs elicit a Th1-type immune response.

The cytokine IL-6 plays an important role in the immunity of mice to tuberculosis (Ladel *et al.*, *Infec. Imm.* 65: 4843-4849, 1997). No secretion of IL-4, a Th2-type cytokine, was detected.

E. Antibody production

Blood samples from BALB/cByJ mice immunized with ME/D were collected two weeks after the last DNA injection and sera prepared according to standard procedures. The presence

of anti-ME/D antibodies was determined by ELISA. As shown in Fig. 8B, high titres of IgG2a antibodies reacting with rME/A and rME/D were detected, but no IgG1 antibodies (Fig. 8A). The presence of IgG2a antibodies is characteristic of a Th1-type immune response.

5 **F. Induction in mice of long-term memory responses by recombinant epitopes and recombinant multi-epitope construct rME/D.**

The induction of long-term memory responses in mice infected with *M. tuberculosis* and immunized with either recombinant epitopes rDNA5, rDNA9A, rDNA26, rDNA27, rDNA37, rDNA44 or rDNA45, or recombinant multi-epitope construct ME/D was determined as follows.

10 In the mouse long-term memory assay, BALB/cByJ mice were injected with a sub-lethal dose of 10^4 colony forming units (CFU) of *M. tuberculosis*. After 4 weeks, the mice were treated with antibiotics for a further 4 weeks to cure them of *M. tuberculosis* infection, followed by a resting period of 8 weeks. A second injection of live *M. tuberculosis* (5×10^5 CFU) was given before the immunogenicity of the recombinant constructs was measured three days later using the 15 spleen cell assay described above. Spleen cells were stimulated with 2 μ M of recombinant epitope or with 1, 0.33, 0.11, 0.03 or 0.01 μ M rME/D. The levels of IFN- γ production determined in the spleen assay are shown in Figs. 9A-C. Spleen cells from control mice were stimulated with the unrelated protein GV14B (Fig. 9B). Other controls in this experiments included stimulation with medium only, 2 μ g/ml ConA, 10 μ g/ml PPD and 10 μ g/ml *M. vaccae* 20 (Fig. 9A). Recombinant ME/D stimulated memory T cells from mice infected with *M. tuberculosis* to produce large amounts of IFN- γ in a dose-dependent manner (Fig. 9B). The production of IFN- γ in this assay is indicative of the cross-reactivity of ME/D with *M. tuberculosis* antigens that induced long-term immune responses. Antigenic determinants cross-reacting with the *M. tuberculosis* antigens appears to be located on epitopes DNA5, 25 DNA9A, DNA26, DNA27 and DNA44 (Fig. 9B).

EXAMPLE 7

EFFECT OF STIMULATION OF HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) WITH RECOMBINANT SINGLE EPITOPE AND RECOMBINANT MULTI-EPITOPE CONSTRUCTS

5

A. Stimulation of Human Peripheral Blood Mononuclear Cells (PBMC) to proliferate and secrete Interferon gamma (IFN- γ) *in vitro*

The recombinant epitopes and recombinant multi-epitope constructs expressed by the pET16 bacterial expression system were cultured with human PBMC at 37 °C. After 48 hours, 10 IFN- γ secretion was measured by enzyme-linked immunoassay (ELISA) as described above. Parallel cultures were pulsed with tritiated thymidine and DNA synthesis was used to assess PBMC proliferation. Results of these experiments are shown in Figs. 10A-B and Figs. 11A-B. The recombinant multi-epitope constructs stimulated human PBMC to secrete IFN- γ and proliferate (Figs. 10A and B, respectively). These responses were dose-dependent and of greater 15 magnitude than the responses induced by the individual recombinant epitopes (Figs. 11A and B).

B. Stimulation of human PBMC by recombinant single epitopes and recombinant multi-epitope constructs rME/A and rME/D to secrete cytokines *in vitro*

Cytokine production of human PBMC were assessed following *in vitro* re-stimulation 20 with recombinant single epitopes or recombinant rME/A or rME/D as follows. Cells were stimulated with 2 μ M of the recombinant single epitopes rDNA5, rDNA9A, rDNA26, rDNA27, rDNA29, rDNA37, rDNA44 or rDNA45, or 0.5 μ M rME/A or rME/D. Cells in the control groups were stimulated with 2 μ M of GV14B or 10 μ g/ml PPD. Cytokine responses was measured by ELISA following standard procedures. As shown in Table 7, below, human PBMC 25 stimulated with the recombinant single epitopes, or with rME/A or rME/D produced the Th1 cytokines IFN- γ and TNF- α . These recombinant epitopes also induced secretion of IL-10. No IL-5, a Th2 cytokine, was detected in supernatants of stimulated cells. Low levels of cytokines were secreted in response to stimulation with the control antigen, and all cytokines tested were secreted by human PBMC after stimulation with PPD.

30

TABLE 7

Cytokine secreted by human PBMC after *in vitro* stimulation with recombinant single epitopes and rME

5

Cytokine	Recombinant single epitopes								rME		Controls	
	DNA 5	DNA 9A	DNA 26	DNA 27	DNA 29	DNA 37	DNA 44	DNA 45	rME/A	rME/D	GV14 B	PPD
IFN- γ	4.7	2.8	4.1	0.06	3.6	4.3	0.45	0.78	4.4	3.2	<0.05	3.96
TNF- α	4.6	<0.05	1.2	0.1	3.5	2.3	0.5	<0.05	3.9	3.8	0.2	0.85
IL-10	0.75	<0.05	0.9	0.15	0.98	0.83	0.59	<0.05	1.17	1.12	0.07	0.34
IL-5	0.08	<0.05	<0.05	0.06	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05	<0.05	0.06

EXAMPLE 8

10

STIMULATION OF LYMPHOCYTE PROLIFERATION IN CYNOMOLGUS MONKEYS
AFTER IMMUNIZATION WITH RECOMBINANT RME/D.

Three groups each consisting of four cynomolgus monkeys were immunized to test the 15 immunogenicity of the recombinant multi-epitope construct rME/D. Proliferation of lymphocytes was measured in a PBMC proliferation assay. The monkeys in Group I were immunized intradermally with PBS in incomplete Freund's adjuvant (IFA) in a total volume of 0.1 ml. Monkeys in Group II were immunized intradermally with 33 μ g rME/D in IFA (total volume 0.1 ml) and monkeys in Group III were immunized intradermally with 10 μ g rME/D in 20 IFA (total volume 0.1 ml). Two immunizations were given, at week 0 and week 6. Blood samples were taken from each monkey 12 weeks after immunization.

Whole blood from each monkey was diluted 1:5 and stimulated with control medium (RPMI 1640 supplemented with 10% (v/v) autologous serum, penicillin (60 μ g/ml), streptomycin (100 μ g/ml), and glutamine (2 mM)) containing either the positive control 25 phytohaemagglutinin (PHA, at 10 μ g/ml), PPD (10 μ g/ml), *M. vaccae* at 10 μ g/ml, rME/D at 1 μ g/ml or control recombinant protein GV-14B at 1 μ g/ml in a total culture volume of 1 ml. The plates were cultured for 72 hours and then pulsed with 1 μ Ci/well of tritiated thymidine for a further 18 hours, harvested and tritium uptake determined using a scintillation counter. Lymphocyte proliferation results are shown in Table 8.

30

TABLE 8

Lymphocyte proliferation in blood samples of cynomolgus monkeys stimulated with PHA, PPD, *M. vaccae*, rME/D or rGV-14.

5

Group	Monkey No.	PHA 10 μ ml	PPD 10 μ ml	<i>M. vaccae</i> 10 μ g/ml	rME/D 1 μ g/ml	rGV-14 1 μ g/ml
1	1	18*	1.3	0.73	1.36	0.77
	2	57	2.3	1.6	2.4	1.5
	3	32	1.6	1.5	1.6	1.0
	4	26	2.2	1.4	1.6	0.91
2	1	23	1.6	0.91	15	0.79
	2	70	2.1	2.0	20	2.2
	3	13	1.0	1.9	12	2.8
	4	40	3.1	2.5	25	3.3
3	1	35	1.2	1.9	18	2.4
	2	81	1.0	1.4	32	2.3
	3	29	1.4	2.2	15	1.3
	4	25	0.89	1.5	1.3	1.0

* Results of PBMC proliferation are expressed as Stimulation Index.

10 As shown in Table 8, the recombinant multi-epitope construct rME/D induced a proliferative response in PBMC cells from immunized monkeys in Groups II and III comparable to that of the positive control (PHA). No proliferation was recorded after stimulation with PPD, *M.vaccae* or rGV-14.

15 Although the present invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, changes and modifications can be carried out without departing from the scope of the invention which is intended to be limited only by the scope of the appended claims.


We claim:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of sequences provided in SEQ ID NO: 61-77.
2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) sequences having at least about 30% identical residues to a sequence recited in any one of SEQ ID NO: 61-63, 65 and 67-77 as determined by computer algorithm FASTX;
 - (b) sequences having at least about 50% identical residues to a sequence recited in any one of SEQ ID NO: 61-63, 65 and 67-77 as determined by computer algorithm FASTX;
 - (c) sequences having at least about 75% identical residues to a sequence recited in SEQ ID NO: 61-77 as determined by computer algorithm FASTX; and
 - (d) sequences having at least about 90% identical residues to a sequence recited in SEQ ID NO: 61-77 as determined by computer algorithm FASTX.
3. An isolated polynucleotide encoding a polypeptide according to any one of claims 1 and 2.
4. The isolated polynucleotide of claim 3, wherein the polynucleotide comprises a sequence selected from the group consisting of sequences recited in SEQ ID NO: 8-21, and complements thereof.
5. An isolated polynucleotide comprising a sequence selected from the group consisting of:
 - (a) sequences having at least about 30% identical residues to a sequence recited in any one of SEQ ID NO: 8-21 as determined by computer algorithm BLASTN;
 - (b) sequences having at least about 50% identical residues to a sequence recited in any one of SEQ ID NO: 8-21 as determined by computer algorithm BLASTN;
 - (c) sequences having at least about 75% identical residues to a sequence recited in SEQ ID NO: 8-21 as determined by computer algorithm BLASTN;
 - (d) sequences having at least about 90% identical residues to a sequence recited in SEQ ID NO: 8-21 as determined by computer algorithm BLASTN; and
 - (e) complements of a sequence of (a), (b), (c) or (d).

6. A DNA construct comprising at least one polynucleotide according to any one of claims 3-5.
7. The DNA construct of claim 6, wherein the construct comprises a sequence selected from the group consisting of SEQ ID NO: 56-58.
8. A host cell transformed with a DNA construct according to any one of claims 6 and 7.
9. A fusion protein comprising at least one polypeptide according to any one of claims 1 and 2.
10. The fusion protein of claim 9, wherein the fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 79-81.
11. A composition comprising at least one polypeptide according to any one of claims 1 and 2, and a physiologically acceptable carrier.
12. A composition comprising at least one polynucleotide according to any one of claims 3-5 and a physiologically acceptable carrier.
13. A composition comprising at least one fusion protein according to claim 9 and a physiologically acceptable carrier.
14. A composition comprising at least one DNA construct according to claim 6, and a physiologically acceptable carrier.
15. A composition comprising at least one polypeptide according to any one of claims 1 and 2, and an immunostimulant.
16. A composition comprising at least one polynucleotide according to any one of claims 3-5 and an immunostimulant.
17. A composition comprising at least one fusion protein according to claim 9 and an immunostimulant.
18. A composition comprising at least one DNA construct according to claim 6 and an immunostimulant.
19. A method for enhancing an immune response in a patient, comprising administering to the patient a composition according to any one of claims 11-18.
20. The method of claim 19, wherein the immune response is a Th1 response.
21. The method of claim 19, wherein the composition activates at least one cell selected from the group consisting of T cells and NK cells.
22. The method of claim 19, wherein the composition stimulates cytokine production.

23. The method of claim 19, wherein the composition induces long-term memory cells.
24. A method for the treatment of a disorder selected from the group consisting of immune disorders, infectious diseases and cancer in a patient, comprising administering to the patient a composition according to any one of claims 11-18.
25. The method of claim 29, wherein the disorder is tuberculosis.

Figure 1
Induction of protective immunity by ME/D vaccination



2 / 11

Figure 2

Proliferative responses by lymph node cells from mouse immunized subcutaneously with recombinant multi-epitope constructs




Figure 3

IFN- γ production by lymph node cells from mice immunized subcutaneously with recombinant multi-epitope constructs





Figure 4**Proliferative responses in mice immunized with
ME/D by different routes**

Figure 5




Figure 6

**Contribution of single epitopes to proliferative responses
in mice immunized with ME/D by different routes**




Figure 7

Contribution of single epitopes to IFN- γ production in mice immunized with ME/D by different routes




Figure 8

**Titre and subclass of anti-ME antibody
in the serum of mice immunized with ME DNA**




Figure 9
IFN- γ production by memory splenocytes of BALB/cByJ mice

■ Memory splenocytes
 □ Control splenocytes





Figure 10

IFN- γ production and proliferative responses of human PBMC after *in vitro* stimulation with rME/A, rME/B and rME/D





Figure 11

IFN- γ and proliferative responses of human PBMC after *in vitro* stimulation with recombinant single epitopes



SEQUENCE LISTING

<110> Delcayre, Alain
<120> Compounds for Treatment of Infectious and Immune System Disorders
and Methods for Their Use

<130> 11000.1042c1PCT

<150> 09/351,348
<151> 1999-07-12
<150> U.S. 09/450,072
<151> 1999-11-29

<160> 81

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 29
<212> DNA
<213> Artificial Sequence ,

<220>
<223> Made in a lab

<400> 1
gagagagaaa gcttatggct acaggctcc 29

<210> 2
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 2
aaggaagggg atcccgaaagc cacagctgcc 30

<210> 3
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 3
aaggaagggg atcccgaaagcc acagctgcc 29

<210> 4
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 4
aaggaagggg atcccgaaag ccacagctgc c, 31

```

<210> 5
<211> 146
<212> DNA
<213> Mycobacterium vaccae

<400> 5
aagcttatgg ctacaggctc ccggacgtcc ctgctcctgg cttttggcct gctctgcctg      60
ccctggcttc aagagggcag tgccttccca accattccct tatccaggct ttttgacaac      120
gctatgcagc tgtggcttcg ggatcc      146

<210> 6
<211> 145
<212> DNA
<213> Mycobacterium vaccae

<400> 6
aagcttatgg ctacaggctc ccggacgtcc ctgctcctgg cttttggcct gctctgcctg      60
ccctggcttc aagagggcag tgccttccca accattccct tatccaggct ttttgacaac      120
gctatgcagc tgtggcttcg gatcc      145

<210> 7
<211> 147
<212> DNA
<213> Mycobacterium vaccae

<400> 7
aagcttatgg ctacaggctc ccggacgtcc ctgctcctgg cttttggcct gctctgcctg      60
ccctggcttc aagagggcag tgccttccca accattccct tatccaggct ttttgacaac      120
gctatgcagc tgtggcttc gggatcc      147

<210> 8
<211> 39
<212> DNA
<213> Mycobacterium vaccae

<400> 8
atcgccgcaca ccggcccggt gcccgccacc gcgtggatc      39

<210> 9
<211> 96
<212> DNA
<213> Mycobacterium vaccae

<400> 9
gttcgtcagt acccgaaagct cttgagagct aaggccaatt gggaaagatac ttggaccttc      60
ccatcaatag agggaaaagca tcgccttagg ggatcc      96

<210> 10
<211> 75
<212> DNA
<213> Mycobacterium vaccae

<400> 10
gtagcggggcc cggtgtttcg agtgaacttg ggcaggcga tcccatcgcg cgcagccgc      60
gcagcggaaa tccac      75

<210> 11
<211> 114
<212> DNA
<213> Mycobacterium vaccae

<400> 11
atcacgcagg taggccccgtcc agccgtactc ttgcggccag aacagcggtg cggtcggccgc      60
gcagaccagc ggtcctgccc ccagatacac ccaggcggtg gccggcatgt ccag      114

```

```

<210> 12
<211> 33
<212> DNA
<213> Mycobacterium vaccae

<400> 12
atcgtggcca ggcgcgcggg cacggtgagg atc 33

<210> 13
<211> 210
<212> DNA
<213> Mycobacterium vaccae

<400> 13
atccgcgcca cggccccggt gcccggcacc gcgtggatcg ttctcgatcgatccggc 60
ttgagagacta agggcaattt ggaagataact tggaccttcc catcaataga gggaaagcat 120
cgccctaggg gatccgttagc gggccccggt tttcgatcgatccggc acttggcag ggcaatccca 180
tcgcgcgcagc cccgcgcagc gggaaatccac 210

<210> 14
<211> 697
<212> DNA
<213> Mycobacterium vaccae

<400> 14
atctactcga ctttcgcgcga cggggcgtac cgggggtggcc tgacgtactc cggccatccg 60
ctggcgaccg ccttcgcgcgt cgcgcgtatc aacgcgtatgg aagacgaaagg catggtggcc 120
aacgtgtccc gcatcgccga gcagggtgtc ggacccgggtc tgctgcgtatc cggccgcgg 180
caccgttcgg tcggcgaatgt cccggccgtc ggcgttctt gggcggtatc cggtgagggtc 240
gtcctgcggc gacttggatgt ccacgttggt gacgcgtatc tccagttccgc caagctgttt 300
caccgtgtcc tcgaccaccg cgcggcgtgt cggccggctcg gccagggtcgc cgggcaggcg 360
gaccgcggcgt tggccggctt ctgcgtatcg tggccaggcgca cggccggcgta 420
cgcgtcgccg tcggcgcgcg gcacggccgcg gcacggggcc acctcccgct cggggcaggc 480
gggtccgtgg accgcagcac ggccgagtcg tttggatcag gtgcgcaccgc cgctgaaccg 540
ggccatcagc gcccggcgtt cggcgcgtc gctgcgggac cggaaacgggc ccaccggcgt 600
gtcgggtgcgc ggcgtgcggc cgggtggagaa cggggggaaag ggttcgtcgatccgc 660
ccaccaccac cgggtgcgggatccgc accgggttgcgtatcg 697

<210> 15
<211> 291
<212> DNA
<213> Mycobacterium vaccae

<400> 15
atcagttcgg ccttcggcgc cagccccggc agggcagccca gttccgttcc ggcgtcgatc 60
gggttgggtc cgttccggccca gcacaccaggc atccaccccgaa ggtcgagccaa cgggtccccg 120
acgggtgcaca tctcccgatc gatgaacggcc gcgagctcg ggcacgtcgatc ggcgcaggc 180
acgttggatca gatggcgtatc gccgtgcgtatc atcccggtt cggcgtcgatc gggcctgcgc 240
gagtccagcc agtccggcgtatc gacatgcacc gacggaaacgc actcggggcgc g 291

<210> 16
<211> 147
<212> DNA
<213> Mycobacterium vaccae

<400> 16
atcacgcagg tagggcgatcc agccgtactc ttccggccatc aacagcggtg cggcgtcgatc 60
gcagaccaggc ggttccggccca ccagatacacc cccaggcgatc ggcggcatgt ccagatcgatc 120
gccagcgccgc ggcggcaccgtt ggagatc 147

<210> 17
<211> 138
<212> DNA

```

<213> *Mycobacterium vaccae*
 <400> 17
 atcgcgccgc tgcgggaa ggacgaggcc gtagccgcgt tgcactacgt cgcccccgtt 60
 ggcgagaagc aggactacat cgaccgagcc ttgcgcaaca tcggggcgta tctgccagct 120
 gaggttcccg ctctcgct 138

<210> 18
 <211> 261
 <212> DNA
 <213> *Mycobacterium vaccae*
 <400> 18
 gatcggcagg catcacgaac agtaagcggt gttccgggtt aatccaatgt gctgtcagca 60
 ggcatccgat gccgaacacc gaccacgcga gcagtcgcga tctgtctcgc gaccctggcg 120
 tcacgcggcg tcgtggctcc gcaacccgcc ggcgatgtcg cgccgcgcgc tgccggccggc 180
 tctccatggc cggttcgttc agtcgctcgt ccgggtggctg ttctgcgaac gggcccgccg 240
 ccccgatcgatc g 261

<210> 19
 <211> 279
 <212> DNA
 <213> *Mycobacterium vaccae*
 <400> 19
 gatctcggtt cgcgtccgcg agatctgcga ccggtagcgc ctggccctaca ccaccgggtc 60
 cttcctgcgc cagtaggcga agtcgtggcg cacgatcgatc aactgtcgc tgccggacaa 120
 gttcctgcgc gacaccgcgc acgacgcccc ggagacccgc agcgagcgga tgttcgccga 180
 actggatccg tcggagcgcc gcgggctgaa gtcggccatc gccgcgggtgc ggtcgccgcg 240
 gcgccaaag gtcgctgcga aagccgcgaa gatcgcgat 279

<210> 20
 <211> 132
 <212> DNA
 <213> *Mycobacterium vaccae*
 <400> 20
 gatccagaac gggccgggtct gcggggtttag gtcctcggtg cccagtgccg tcgacgcgac 60
 gtcgtccgcg tcgtgtatgc ggccgcgtt ggcgtccctcg gtccacaacg tcagcaccgt 120
 gcccggccgg at 132

<210> 21
 <211> 177
 <212> DNA
 <213> *Mycobacterium vaccae*
 <400> 21
 gatcagctcg gggagccggg tgcccagcaa cgccagcggt ggaagcaccg agaccggcg 60
 gatgtcccg cgcagcagcg cccagccgtg caccggcg gaccggggccc cgccggaccgc 120
 gtcggatcg accccggcccg ccaccggccgc ggcgtggtc agcatcagcc acggat 177

<210> 22
 <211> 15
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Made in a lab
 <400> 22
 cgcagctgtg gcttc 15

<210> 23
 <211> 22

```

<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 23
ttacttaggt tactagtggta tc

<210> 24
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 24
cgatctactc gaccgtcgcc gac

<210> 25
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 25
ttacgccccag aagacgcccga ggcc

<210> 26
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 26
gatccccatca ccatcaccat cactga

<210> 27
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 27
ggtagtggtta gtggtagtga cttaa

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 28
atggctacag gctccggac

```

22

23

24

26

26

20

<210> 29
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 29
gagagagaga tctgtggatt tccgctgcgc gggc 34

<210> 30
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 30
gagagagaga tctcgcgccc gagtcgttcc cgtc 34

<210> 31
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 31
gagagagaga tctgatctcc accgtgccgc gcgc 34

<210> 32
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 32
gagagagaga tctgacgaga gcggggacacct cagc 34

<210> 33
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 33
gagagagaga tctatcgcgta tcttcgcggc ttcc 34

<210> 34
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Made in a lab

<400> 34

gagagagaga tctatccgcc cgggcacggt gctg	34
<210> 35	
<211> 34	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Made in a lab	
<400> 35	
gagagagaga tctatcccgt ggctgatgct gacc	34
<210> 36	
<211> 36	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Made in a lab	
<400> 36	
gagagagaga tctcgtatcg gacggacgac gggacg	36
<210> 37	
<211> 35	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Made in a lab	
<400> 37	
gagagagagg atcccaaccg gcggtcgaag ttccc	35
<210> 38	
<211> 36	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Made in a lab	
<400> 38	
aaggaaggaa aaggatccgg gaatggttgg gaaggc	36
<210> 39	
<211> 126	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Made in a lab	
<400> 39	
aagcttatgg ctacaggctc ccggacgtcc ctgctcctgg cttttggcct gctctgcctg	60
ccctggcttc aagagggcag tgccttcca accattcccg gatcccacca tcatcaccat	120
cactga	126
<210> 40	
<211> 35	
<212> DNA	
<213> Artificial Sequence	

<220>		
<223> Made in a lab		
<400> 40		
gagagagaga tctatctact cgacacctcgcc cgacc		35
<210> 41		
<211> 37		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Made in a lab		
<400> 41		
aaggaaggaa ggatcccgcc cagaagacgc cgaggcc		37
<210> 42		
<211> 34		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Made in a lab		
<400> 42		
gagagagaga tctatcagtt cggccctggc cgcc		34
<210> 43		
<211> 37		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Made in a lab		
<400> 43		
aaggaaggaa ggatcccgcg cccgagtcgt tcccgtc		37
<210> 44		
<211> 35		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Made in a lab		
<400> 44		
gagagagaga tctgatcggc aggcatcacg aacag		35
<210> 45		
<211> 37		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Made in a lab		
<400> 45		
aaggaaggaa ggatcccgta tcggacggac gacgggg		37
<210> 46		
<211> 34		
<212> DNA		

<213> Artificial Sequence	
<220>	
<223> Made in a lab	
<400> 46	
gagagagaga tctgatccag aacggggccgg tctg	34
<210> 47	
<211> 37	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Made in a lab	
<400> 47	
aaggaaggaa ggatccatcc gccccggcac ggtgctg	37
<210> 48	
<211> 35	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Made in a lab	
<400> 48	
gagagagaga tctgatcagc tcggggagcc gggtg	35
<210> 49	
<211> 37	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Made in a lab	
<400> 49	
aaggaaggaa ggatccatcc cgtggctgat gctgacc	37
<210> 50	
<211> 22	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Made in a lab	
<400> 50	
tatcgccgccc accggccggc tg	22
<210> 51	
<211> 22	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Made in a lab	
<400> 51	
cgtggatttc cgctgcgcgg gc	22
<210> 52	

<211> 33		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Made in a lab		
<400> 52		
gagagagaga tctatcacgc aggtaggccg tcc	33	
<210> 53		
<211> 37		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Made in a lab		
<400> 53		
aaggaaggaa ggatccgatc tccaccgtgc cgcgcg	37	
<210> 54		
<211> 35		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Made in a lab		
<400> 54		
gagagagaga tctatcgcgc ggctgtgcgg gaagg	35	
<210> 55		
<211> 37		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Made in a lab		
<400> 55		
aaggaaggaa ggatccgacg agagcgggaa cctcagc	37	
<210> 56		
<211> 1749		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Made in a lab		
<400> 56		
atggctacag gtccttgcgc gtccctgtc ctggcttttgc gcctgctctg cctggccctgg	60	
cttcaagagg gcagtgcctt cccaaaccatt cccggatcta tctactcgac ctgcgcgcac	120	
cggggcttacc cgggtggccct gacgtactcc ggccatccgc tggcgaccgc ctgcgcgggtc	180	
gcgacgatca acgcgatggaa agacgaaggc atggtgccca acgctgccccg catcggcgag	240	
caggtgctcg gaccgggtctt ggcgcgtatctc gcccggcgc accgttcggt cggcgaagtc	300	
cggggcttcg gcgtcttctg ggcgggatct gatccagaac gggccggctc gcggtttag	360	
gtcctcggtt cccagtgccg tcgacgcgcac gtcgtccgc ctggatgtgc ggccggcgta	420	
ggcggtccctcg gtccacaacg tcagcacccgt gcccgggggg atggatctga tcggcaggca	480	
tcacgaacag taagcggtgt tccgggttga tccaaatgtgc tgcgtcagg catcccgatgc	540	
cgaacacccga ccacgcgagc agtcgcaatc tgcgtccgc cccctggcgac acgcggcgac	600	
gtggctccgc aacccggccgg cgatgtcgcc cgccggcgctc tccatggccg	660	
gttcgttccag tgcgtcgcc ggtggctgtt ctgcgaacgg gcccggccgc cccgtcgcc	720	

tccgataacgg	gatctgatca	gctcgaaaa	ccgggtgccc	agcaacgcca	gcgtggaaag	783
caccgagacc	ggcgcgatgt	gcccgcgac	cagccccag	ccgtgcaccc	cgccccggaccg	840
ggcccccgg	accgcgtcg	agtcgaccc	ggccgcacc	gccgcgcgcg	tggtcagcat	900
cagccacggg	atggatctat	cagttcgcc	ctggcgcca	gccccggcag	ggcagccagt	960
tccgctccgg	cgtcgatcg	gttgggtccg	tccggccag	acaccagcat	ccacccggagg	1020
tcgagcaacg	ggtccccggac	gttgcacatc	tcccagtca	tgaacgcgc	gagctcgggg	1080
acgtcgccgc	gcagcagcac	gttgcata	tggcagtgc	cgtgcatgt	cccgggttcg	1140
gcgtcgccg	gcctgcgcga	gtccagccag	tcggcgagca	catgcaccga	cggaaacgac	1200
tcgggcccgg	gatctatcac	gcaggtaggc	cgtccagccg	tactcttcgc	cccagaacag	1260
cggtgcgc	gcccgcaga	ccagcggtcc	tgcccgcaga	tacacccagg	cggtggccgg	1320
catgtccaga	tcgtggccag	cgcgcgcgc	acgggtggaga	tggatctat	cgcgcgcgtg	1380
tgcggaaagg	acgaggccgt	agcggcggt	cactacgtcg	ccccgggttg	cgagaagcag	1440
gactacatcg	accgcgttt	gcgcacatc	ggccgtatc	tgccagctga	ggttcccgct	1500
ctcgccgtat	ctatgcgcgc	caccggcccg	gtgcccggca	ccgcgtggat	cgttcgtcag	1560
tacccgaagc	tcttgagagc	taaggccaat	tggaaagata	cttggacctt	cccatcaata	1620
gaggaaaagc	atgcgcctag	gggatccgta	gcggggccgg	tgtttcgagt	gaacttgggc	1680
agggcaatcc	catcgcgcc	agcccgccga	gcggaaatcc	acggatccca	tcaccatcac	1740
catcaactga						1749

<210> 57
 <211> 1749
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 57						
atggctacag	gctcccgac	gtccctgtc	ctggctttg	gcctgctctg	cctgcccgtgg	60
cttcaagagg	gcagtgcctt	cccaaccatt	cccgatcta	tctactcgac	cttcgcgcac	120
cggcgatacc	cgggtggccct	gacgtactcc	ggccatccgc	tggcaccgc	ctgcgcggtc	180
gcgcacatca	acgcgatgg	agacgaaggc	atggtggcca	acgctgccc	catcgccag	240
caggtgtcg	gaccgggtct	gcgcgatctc	gcccggccgc	accgttcgg	cggcgaagtc	300
cgcggctcg	gcgtttctg	ggcgggatct	atcagttcg	ccctggtcgc	cagcccgg	360
agggcagcca	gttccgctcc	ggcgtcgatc	gggttgggtc	cgtggccca	gcacaccagc	420
atccacccga	ggtcgagcaa	cgggtccccc	acggtgacata	tctccca	gatgaacgccc	480
gcgagctcg	ggacgtcg	gcgcagcgc	atgttgcata	gtggcagtc	gccgtgcatg	540
atcccggtt	cgcgctcg	ggcctgtcgc	gagtccagcc	agtcggcag	cacatgcacc	600
gacggaaacg	actcgggcgc	gggatctgt	cgccaggcat	cacgaacagt	aagcgtgtt	660
ccgggttaat	ccaatgtgt	gtcagcaggc	atccgatgcc	gaacaccgc	cacgcgagca	720
gtcgcaatct	gtctcgcgac	cctggcgatc	cgccgcgtcg	tggctccgca	acccgcggc	780
gatgtcg	gcgcgcgtc	ggccggctct	ccatggccgg	ttcggtcag	cgtcgcccg	840
gtggctttc	tgcgaacggg	cccgccggcc	cgtcgccgt	ccgatacgg	atctgatcag	900
ctcggggagc	cgggtggccca	gcaacgcac	cgtggaaagc	accgagaccg	gcgcgtatgt	960
cccgcgcagc	agcgcccgac	cgtgcaccc	gggggacccgg	gccccgcgg	ccgcgtcgga	1020
gtcgaccccg	gcccgcaccc	ccgcgcgt	ggtcagcatc	agccacggg	tggatctatc	1080
acgcaggtag	gcccgtccagc	cgtactctc	gccccagaac	agcgggtccgg	tcgcccgcga	1140
gaccaggcg	cctgcccgc	gatacacc	ggcgggtggcc	ggcatgtcc	gatcggtggcc	1200
agcgcgcgc	gcacgggt	gatcggtatc	atcgcgcggc	tgtgcgggaa	ggacgaggcc	1260
gtagcggt	tgcactacgt	cggcccggt	ggcgagaagc	aggactacat	cgaccgagcc	1320
ttgcgaaca	tcggccgt	tctgccc	gaggttcccg	cttcgtcg	atctgatcca	1380
gaacggccg	gtctcggt	tgaggcc	ggtgccc	ggcgtcgac	cgacgtcg	1440
ggcgtgt	atgcggccgc	cgtaggcg	ctcggtccac	aacgtcagca	ccgtgcccgg	1500
gcggatgt	ctatcgccgc	caccggcc	gtgcccggca	ccgcgtggat	cgttcg	1560
tacccgaagc	tcttgagagc	taaggccaat	tggaaagata	cttggacctt	cccatcaata	1620
gaggaaaagc	atgcgcctag	gggatccgta	gcggggccgg	tgtttcgagt	gaacttggc	1680
agggcaatcc	catcgcgcc	agcccgccga	gcggaaatcc	acggatccca	tcaccatcac	1740
catcaactga						1749

<210> 58
 <211> 1749
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Made in a lab

 <400> 58

atggctacag	gctcccgac	gtccctgtctc	ctggcttttgc	gcctgtctcg	cctgcctgg	60
cttcaagagg	gcagtgcctt	cccaaccatt	cccgatcta	tctactcgac	cttcggccgac	120
cgggcgtacc	cgggtggcct	gacgtactcc	ggccatccgc	tggcgaccgc	ctgcgcggtc	180
gacgatca	acggatgga	agacgaaggc	atggtggcca	acgctgccccg	catcgccgag	240
caggtgtcg	gaccgggtct	gcccgtatctc	gccgccccggc	accgttcggt	cggcgaagtc	300
cgcggctcg	gcgtttctg	ggcgggatct	gatccagaac	ggggccggct	gcgggttgag	360
gtcctcggtg	cccaagtgcgc	tcgacgcgc	gtcgtcgccg	ctgggtatgc	ggccggccgta	420
ggcgtctcg	gtccacaaacg	tcagcacccgt	gccccggcgg	atggatctat	cagttcgcc	480
ctggtcgcca	gccccccgag	ggcagccgt	tccgtcccg	cgtcgatcg	gttgggtccg	540
tccggccagc	acaccagcat	ccacccggagg	tcgagcaacg	gttcccccgc	gtgcacatc	600
tcccagtgcg	tgaacgcgc	gagctcgcccc	acgctcgccgc	gcagcagcac	gttggttcaga	660
tggcagtgcg	cgtgcgtat	cccggttctg	gcgtcgccgg	gcctgcgcga	gtccagccag	720
tcggcggacg	catgcaccga	cgggaaacgc	tcggcgcgg	gatctgtatca	gttcggggag	780
ccgggtgccc	agcaacgcgc	gcgtggaaag	caccgagacc	ggcgcgtatgt	gcccggcgcag	840
cagcggccag	cgtgcaccc	cgccggaccc	ggcccccggc	accgcgtcg	agtcgaccccc	900
ggccgcacc	gcccgcgcg	tggtcagcat	cagccacccgg	atggatctga	tcggcaggca	960
tcacgaaacg	taagcggtgt	tccgggttga	tccaatgtgc	tgtcagcagg	catccgatgc	1020
cgaacaccga	ccacgcgagc	agtcgcaatc	tgtctcgca	ccctggcgctc	acgcggcgctc	1080
gtggctccgc	aaccgcgcgg	cgatgtcgcc	cgcggcgctc	ccggccggctc	tccatggccg	1140
gttcgttcag	tgcgtcgatcc	ggtggctgtt	ctgcgaacgg	ggccgcggcc	ccgtctgtccg	1200
tccgatacgg	gatctatcac	gcaggtaggc	cgtccagccg	tactcttcgc	cccagaacag	1260
cggtgcgtc	gcccgcgcaga	ccagcggtcc	tgccgcgcaga	tacacccagg	cggtgccgg	1320
catgtccaga	tcgtggccag	cgcgcgcggc	acggtgggaga	tcggatctat	cgcgcggctg	1380
tgcggaaagg	acgaggccgt	agcggcgttg	caactacgtc	ccccgggttgg	cgagaagcag	1440
gactacatcg	accgagcctt	gcccgcgcgc	gggcgtatc	tgccagctga	gttcccccgt	1500
ctcgctcgat	ctatcgccgc	caccggcccg	gtgcccggca	cgcgcgtggat	cgttcgctcag	1560
tacccgaaagc	tcttgagac	taaggccaaat	tggaaagata	cttggacctt	cccatcaata	1620
aggcaatcc	atcgccctag	gggatccgt	gccccggccgg	tgtttcgag	gaacttggc	1680
cgatctactc	gacccgcgc	agccgcgcgc	gccccggccgg	acggatccca	tcaccatcac	1740
catcaactga						1749

<210> 59
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 59

cgatctactc	gacccgcgc	gac		23
------------	-----------	-----	--	----

<210> 60
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 60

tcagtggatt	tccgctgcgc	gggc		24
------------	------------	------	--	----

<210> 61
 <211> 46
 <212> PRT
 <213> *Mycobacterium vaccae*

<400> 61
 Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu

1	5	10	15												
Cys	Leu	Pro	Trp	Leu	Gln	Glu	Gly	Ser	Ala	Phe	Pro	Thr	Ile	Pro	Leu
20								25						30	
Ser	Arg	Leu	Phe	Asp	Asn	Ala	Met	Gln	Leu	Trp	Leu	Arg	Asp		
35								40						45	

<210> 62
<211> 46
<212> PRT
<213> *Mycobacterium vaccae*

1	5	10	15												
Met	Ala	Thr	Gly	Ser	Arg	Thr	Ser	Leu	Leu	Leu	Ala	Phe	Gly	Leu	Leu
20								25						30	
Ser	Arg	Leu	Phe	Asp	Asn	Ala	Met	Gln	Leu	Trp	Leu	Arg	Ile		
35								40						45	

<210> 63
<211> 46
<212> PRT
<213> *Mycobacterium vaccae*

1	5	10	15												
Met	Ala	Thr	Gly	Ser	Arg	Thr	Ser	Leu	Leu	Leu	Ala	Phe	Gly	Leu	Leu
20								25						30	
Ser	Arg	Leu	Phe	Asp	Asn	Ala	Met	Gln	Leu	Trp	Leu	Pro	Gly		
35								40						45	

<210> 64
<211> 13
<212> PRT
<213> *Mycobacterium vaccae*

1	5	10												
Ile	Ala	Ala	Thr	Gly	Pro	Val	Pro	Gly	Thr	Ala	Trp	Ile		

<210> 65
<211> 32
<212> PRT
<213> *Mycobacterium vaccae*

1	5	10	15												
Val	Arg	Gln	Tyr	Pro	Lys	Leu	Leu	Arg	Ala	Lys	Ala	Asn	Trp	Glu	Asp
20								25						30	
Thr	Trp	Thr	Phe	Pro	Ser	Ile	Glu	Glu	Lys	His	Arg	Pro	Arg	Gly	Ser

<210> 66
<211> 25
<212> PRT
<213> *Mycobacterium vaccae*

1	5	10	15												
Val	Ala	Gly	Pro	Val	Phe	Arg	Val	Asn	Leu	Gly	Arg	Ala	Ile	Pro	Ser
20															
Arg	Ala	Ala	Arg	Ala	Ala	Glu	Ile	His							
								25							

<210> 67

<211> 38
 <212> PRT
 <213> *Mycobacterium vaccae*

<400> 67
 Ile Thr Gln Val Gly Arg Pro Ala Val Leu Phe Ala Pro Glu Gln Arg
 1 5 10 15
 Cys Arg Arg Arg Ala Asp Gln Arg Ser Cys Arg Gln Ile His Pro Gly
 20 25 30
 Gly Gly Arg His Val Gln
 35

<210> 68
 <211> 11
 <212> PRT
 <213> *Mycobacterium vaccae*

<400> 68
 Ile Val Ala Ser Ala Arg Gly Thr Val Glu Ile
 1 5 10

<210> 69
 <211> 70
 <212> PRT
 <213> *Mycobacterium vaccae*

<400> 69
 Ile Ala Ala Thr Gly Pro Val Pro Gly Thr Ala Trp Ile Val Arg Gln
 1 5 10 15
 Tyr Pro Lys Leu Leu Arg Ala Lys Ala Asn Trp Glu Asp Thr Trp Thr
 20 25 30
 Phe Pro Ser Ile Glu Glu Lys His Arg Pro Arg Gly Ser Val Ala Gly
 35 40 45
 Pro Val Phe Arg Val Asn Leu Gly Arg Ala Ile Pro Ser Arg Ala Ala
 50 55 60
 Arg Ala Ala Glu Ile His
 65 70

<210> 70
 <211> 75
 <212> PRT
 <213> *Mycobacterium vaccae*

<400> 70
 Ile Tyr Ser Thr Phe Ala Asp Arg Ala Tyr Pro Gly Gly Leu Thr Tyr
 1 5 10 15
 Ser Gly His Pro Leu Ala Thr Ala Cys Ala Val Ala Thr Ile Asn Ala
 20 25 30
 Met Glu Asp Glu Gly Met Val Ala Asn Ala Ala Arg Ile Gly Glu Gln
 35 40 45
 Val Leu Gly Pro Gly Leu Arg Asp Leu Ala Ala Arg His Arg Ser Val
 50 55 60
 Gly Glu Val Arg Gly Leu Gly Val Phe Trp Ala
 65 70 75

<210> 71
 <211> 97
 <212> PRT
 <213> *Mycobacterium vaccae*

<400> 71
 Ile Ser Ser Ala Leu Val Ala Ser Pro Pro Arg Ala Ala Ser Ser Ala
 1 5 10 15
 Pro Ala Ser Ile Gly Leu Gly Pro Ser Gly Gln His Thr Ser Ile His

20	25	30	
Pro Arg Ser Ser Asn Gly Ser Pro Thr Val His Ile Ser Gln Ser Met			
35	40	45	
Asn Ala Ala Ser Ser Gly Thr Ser Arg Arg Ser Ser Thr Leu Phe Arg			
50	55	60	
Trp Gln Ser Pro Cys Met Ile Pro Gly Ser Ala Ser Ser Gly Leu Arg			
65	70	75	80
Glu Ser Ser Gln Ser Ala Ser Thr Cys Thr Asp Gly Asn Asp Ser Gly			
85	90	95	
Ala			

<210> 72
 <211> 49
 <212> PRT
 <213> *Mycobacterium vaccae*

<400> 72			
Ile Thr Gln Val Gly Arg Pro Ala Val Leu Phe Ala Pro Glu Gln Arg			
1	5	10	15
Cys Arg Arg Ala Asp Gln Arg Ser Cys Arg Gln Ile His Pro Gly			
20	25	30	
Gly Gly Arg His Val Gln Ile Val Ala Ser Ala Arg Gly Thr Val Glu			
35	40	45	
Ile			

<210> 73
 <211> 46
 <212> PRT
 <213> *Mycobacterium vaccae*

<400> 73			
Ile Ala Arg Leu Cys Gly Lys Asp Glu Ala Val Ala Ala Leu His Tyr			
1	5	10	15
Val Ala Pro Val Gly Glu Lys Gln Asp Tyr Ile Asp Arg Ala Leu Arg			
20	25	30	
Asn Ile Gly Pro Tyr Leu Pro Ala Glu Val Pro Ala Leu Val			
35	40	45	

<210> 74
 <211> 87
 <212> PRT
 <213> *Mycobacterium vaccae*

<400> 74			
Asp Arg Gln Ala Ser Arg Thr Val Ser Gly Val Pro Val Glu Ser Asn			
1	5	10	15
Val Leu Ser Ala Gly Ile Arg Cys Arg Thr Pro Thr Thr Arg Ala Val			
20	25	30	
Ala Ile Cys Leu Ala Thr Leu Ala Ser Arg Gly Val Val Ala Pro Gln			
35	40	45	
Pro Ala Gly Asp Val Ala Arg Ala Ala Ala Gly Ser Pro Trp Pro			
50	55	60	
Val Arg Ser Val Ala Arg Pro Val Ala Val Leu Arg Thr Gly Pro Pro			
65	70	75	80
Pro Arg Arg Pro Ser Asp Thr			
85			

<210> 75
 <211> 93
 <212> PRT
 <213> *Mycobacterium vaccae*

<400> 75
 Asp Leu Val Ala Arg Pro Arg Asp Leu Arg Pro Val Arg Pro Ala Leu
 1 5 10 15
 His His Arg Val Leu Pro Gly Ala Val Arg Gln Val Val Ala His Asp
 20 25 30
 Arg Glu Thr Val Ala Ala Gly Gln Val Pro Ala Arg His Arg Arg Arg
 35 40 45
 Arg Pro Gly Asp Pro Gln Arg Ala Asp Val Arg Arg Thr Gly Ser Val
 50 55 60
 Gly Ala Ala Arg Ala Glu Val Gly His Arg Arg Gly Ala Val Ala Pro
 65 70 75 80
 Ala Arg Gln Gly Arg Cys Glu Ser Arg Glu Asp Arg Asp
 85 90

<210> 76
 <211> 44
 <212> PRT
 <213> *Mycobacterium vaccae*

<400> 76
 Asp Pro Glu Arg Ala Gly Leu Arg Val Glu Val Leu Gly Ala Gln Cys
 1 5 10 15
 Arg Arg Arg Asp Val Val Gly Ala Gly Asp Ala Ala Ala Val Gly Val
 20 25 30
 Leu Gly Pro Gln Arg Gln His Arg Ala Arg Ala Asp
 35 40

<210> 77
 <211> 59
 <212> PRT
 <213> *Mycobacterium vaccae*

<400> 77
 Asp Gln Leu Gly Glu Pro Gly Ala Gln Gln Arg Gln Arg Gly Lys His
 1 5 10 15
 Arg Asp Arg Arg Asp Val Pro Ala Gln Gln Arg Pro Ala Val His Pro
 20 25 30
 Ala Gly Pro Gly Pro Ala Asp Arg Val Gly Val Asp Pro Gly Arg His
 35 40 45
 Arg Arg Ala Arg Gly Gln His Gln Pro Arg Asp
 50 55

<210> 78
 <211> 39
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 78
 Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu
 1 5 10 15
 Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile Pro Gly
 20 25 30
 Ser His His His His His
 35

<210> 79
 <211> 582
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Made in a lab

<400> 79
 Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu
 1 5 10 15
 Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile Pro Gly
 20 25 30
 Ser Ile Tyr Ser Thr Phe Ala Asp Arg Ala Tyr Pro Gly Gly Leu Thr
 35 40 45
 Tyr Ser Gly His Pro Leu Ala Thr Ala Cys Ala Val Ala Thr Ile Asn
 50 55 60
 Ala Met Glu Asp Glu Gly Met Val Ala Asn Ala Ala Arg Ile Gly Glu
 65 70 75 80
 Gln Val Leu Gly Pro Gly Leu Arg Asp Leu Ala Ala Arg His Arg Ser
 85 90 95
 Val Gly Glu Val Arg Gly Leu Gly Val Phe Trp Ala Gly Ser Asp Pro
 100 105 110
 Glu Arg Ala Gly Leu Arg Val Glu Val Leu Gly Ala Gln Cys Arg Arg
 115 120 125
 Arg Asp Val Val Gly Ala Gly Asp Ala Ala Val Gly Val Leu Gly
 130 135 140
 Pro Gln Arg Gln His Arg Ala Arg Ala Asp Gly Ser Asp Arg Gln Ala
 145 150 155 160
 Ser Arg Thr Val Ser Gly Val Pro Val Glu Ser Asn Val Leu Ser Ala
 165 170 175
 Gly Ile Arg Cys Arg Thr Pro Thr Thr Arg Ala Val Ala Ile Cys Leu
 180 185 190
 Ala Thr Leu Ala Ser Arg Gly Val Val Ala Pro Gln Pro Ala Gly Asp
 195 200 205
 Val Ala Arg Ala Ala Ala Ala Gly Ser Pro Trp Pro Val Arg Ser Val
 210 215 220
 Ala Arg Pro Val Ala Val Leu Arg Thr Gly Pro Pro Pro Arg Arg Pro
 225 230 235 240
 Ser Asp Thr Gly Ser Asp Gln Leu Gly Glu Pro Gly Ala Gln Gln Arg
 245 250 255
 Gln Arg Gly Lys His Arg Asp Arg Arg Asp Val Pro Ala Gln Gln Arg
 260 265 270
 Pro Ala Val His Pro Ala Gly Pro Gly Pro Ala Asp Arg Val Gly Val
 275 280 285
 Asp Pro Gly Arg His Arg Arg Ala Arg Gly Gln His Gln Pro Arg Asp
 290 295 300
 Gly Ser Ile Ser Ser Ala Leu Val Ala Ser Pro Pro Arg Ala Ala Ser
 305 310 315 320
 Ser Ala Pro Ala Ser Ile Gly Leu Gly Pro Ser Gly Gln His Thr Ser
 325 330 335
 Ile His Pro Arg Ser Ser Asn Gly Ser Pro Thr Val His Ile Ser Gln
 340 345 350
 Ser Met Asn Ala Ala Ser Ser Gly Thr Ser Arg Arg Ser Ser Thr Leu
 355 360 365
 Phe Arg Trp Gln Ser Pro Cys Met Ile Pro Gly Ser Ala Ser Ser Gly
 370 375 380
 Leu Arg Glu Ser Ser Gln Ser Ala Ser Thr Cys Thr Asp Gly Asn Asp
 385 390 395 400
 Ser Gly Ala Gly Ser Ile Thr Gln Val Gly Arg Pro Ala Val Leu Phe
 405 410 415
 Ala Pro Glu Gln Arg Cys Arg Arg Ala Asp Gln Arg Ser Cys Arg
 420 425 430
 Gln Ile His Pro Gly Gly Arg His Val Gln Ile Val Ala Ser Ala
 435 440 445
 Arg Gly Thr Val Glu Ile Gly Ser Ile Ala Arg Leu Cys Gly Lys Asp
 450 455 460
 Glu Ala Val Ala Ala Leu His Tyr Val Ala Pro Val Gly Glu Lys Gln
 465 470 475 480
 Asp Tyr Ile Asp Arg Ala Leu Arg Asn Ile Gly Pro Tyr Leu Pro Ala

485	490	495
Glu Val Pro Ala Leu Val Gly Ser Ile Ala Ala Thr Gly Pro Val Pro		
500	505	510
Gly Thr Ala Trp Ile Val Arg Gln Tyr Pro Lys Leu Leu Arg Ala Lys		
515	520	525
Ala Asn Trp Glu Asp Thr Trp Thr Phe Pro Ser Ile Glu Glu Lys His		
530	535	540
Arg Pro Arg Gly Ser Val Ala Gly Pro Val Phe Arg Val Asn Leu Gly		
545	550	555
Arg Ala Ile Pro Ser Arg Ala Ala Arg Ala Ala Glu Ile His Gly Ser		
565	570	575
His His His His His		
580		

<210> 80
 <211> 582
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Made in a lab

<400> 80		
Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu		
1	5	10
Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile Pro Gly		
20	25	30
Ser Ile Tyr Ser Thr Phe Ala Asp Arg Ala Tyr Pro Gly Gly Leu Thr		
35	40	45
Tyr Ser Gly His Pro Leu Ala Thr Ala Cys Ala Val Ala Thr Ile Asn		
50	55	60
Ala Met Glu Asp Glu Gly Met Val Ala Asn Ala Ala Arg Ile Gly Glu		
65	70	75
Gln Val Leu Gly Pro Gly Leu Arg Asp Leu Ala Ala Arg His Arg Ser		
85	90	95
Val Gly Glu Val Arg Gly Leu Gly Val Phe Trp Ala Gly Ser Ile Ser		
100	105	110
Ser Ala Leu Val Ala Ser Pro Pro Arg Ala Ala Ser Ser Ala Pro Ala		
115	120	125
Ser Ile Gly Leu Gly Pro Ser Gly Gln His Thr Ser Ile His Pro Arg		
130	135	140
Ser Ser Asn Gly Ser Pro Thr Val His Ile Ser Gln Ser Met Asn Ala		
145	150	155
Ala Ser Ser Gly Thr Ser Arg Arg Ser Ser Thr Leu Phe Arg Trp Gln		
165	170	175
Ser Pro Cys Met Ile Pro Gly Ser Ala Ser Ser Gly Leu Arg Glu Ser		
180	185	190
Ser Gln Ser Ala Ser Thr Cys Thr Asp Gly Asn Asp Ser Gly Ala Gly		
195	200	205
Ser Asp Arg Gln Ala Ser Arg Thr Val Ser Gly Val Pro Val Glu Ser		
210	215	220
Asn Val Leu Ser Ala Gly Ile Arg Cys Arg Thr Pro Thr Thr Arg Ala		
225	230	235
Val Ala Ile Cys Leu Ala Thr Leu Ala Ser Arg Gly Val Val Ala Pro		
245	250	255
Gln Pro Ala Gly Asp Val Ala Arg Ala Ala Ala Gly Ser Pro Trp		
260	265	270
Pro Val Arg Ser Val Ala Arg Pro Val Ala Val Leu Arg Thr Gly Pro		
275	280	285
Pro Pro Arg Arg Pro Ser Asp Thr Gly Ser Asp Gln Leu Gly Glu Pro		
290	295	300
Gly Ala Gln Gln Arg Gln Arg Gly Lys His Arg Asp Arg Arg Asp Val		
305	310	315
Pro Ala Gln Gln Arg Pro Ala Val His Pro Ala Gly Pro Gly Pro Ala		

325	330	335
Asp Arg Val Gly Val Asp Pro Gly Arg His Arg Arg Ala Arg Gly Gln		
340	345	350
His Gln Pro Arg Asp Gly Ser Ile Thr Gln Val Gly Arg Pro Ala Val		
355	360	365
Leu Phe Ala Pro Glu Gln Arg Cys Arg Arg Arg Ala Asp Gln Arg Ser		
370	375	380
Cys Arg Gln Ile His Pro Gly Gly Arg His Val Gln Ile Val Ala		
385	390	395
Ser Ala Arg Gly Thr Val Glu Ile Gly Ser Ile Ala Arg Leu Cys Gly		
405	410	415
Lys Asp Glu Ala Val Ala Ala Leu His Tyr Val Ala Pro Val Gly Glu		
420	425	430
Lys Gln Asp Tyr Ile Asp Arg Ala Leu Arg Asn Ile Gly Pro Tyr Leu		
435	440	445
Pro Ala Glu Val Pro Ala Leu Val Gly Ser Asp Pro Glu Arg Ala Gly		
450	455	460
Leu Arg Val Glu Val Leu Gly Ala Gln Cys Arg Arg Arg Asp Val Val		
465	470	475
Gly Ala Gly Asp Ala Ala Ala Val Gly Val Leu Gly Pro Gln Arg Gln		
485	490	495
His Arg Ala Arg Ala Asp Gly Ser Ile Ala Ala Thr Gly Pro Val Pro		
500	505	510
Gly Thr Ala Trp Ile Val Arg Gln Tyr Pro Lys Leu Leu Arg Ala Lys		
515	520	525
Ala Asn Trp Glu Asp Thr Trp Thr Phe Pro Ser Ile Glu Glu Lys His		
530	535	540
Arg Pro Arg Gly Ser Val Ala Gly Pro Val Phe Arg Val Asn Leu Gly		
545	550	555
Arg Ala Ile Pro Ser Arg Ala Ala Arg Ala Ala Glu Ile His Gly Ser		
565	570	575
His His His His His		
580		

<210> 81

<211> 582

<212> PRT

<213> Artificial Sequence

<220>

<223> Made in a lab

<400> 81

Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu		
1	5	10
Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Phe Pro Thr Ile Pro Gly		
20	25	30
Ser Ile Tyr Ser Thr Phe Ala Asp Arg Ala Tyr Pro Gly Gly Leu Thr		
35	40	45
Tyr Ser Gly His Pro Leu Ala Thr Ala Cys Ala Val Ala Thr Ile Asn		
50	55	60
Ala Met Glu Asp Glu Gly Met Val Ala Asn Ala Ala Arg Ile Gly Glu		
65	70	75
Gln Val Leu Gly Pro Gly Leu Arg Asp Leu Ala Ala Arg His Arg Ser		
85	90	95
Val Gly Glu Val Arg Gly Leu Gly Val Phe Trp Ala Gly Ser Asp Pro		
100	105	110
Glu Arg Ala Gly Leu Arg Val Glu Val Leu Gly Ala Gln Cys Arg Arg		
115	120	125
Arg Asp Val Val Gly Ala Gly Asp Ala Ala Ala Val Gly Val Leu Gly		
130	135	140
Pro Gln Arg Gln His Arg Ala Arg Ala Asp Gly Ser Ile Ser Ser Ala		
145	150	155
Leu Val Ala Ser Pro Pro Arg Ala Ala Ser Ser Ala Pro Ala Ser Ile		

Gly	Leu	Gly	Pro	Ser	165	Gly	Gln	His	Thr	Ser	Ile	His	Pro	Arg	Ser	Ser	
					180										190		
Asn	Gly	Ser	Pro	Thr	185	Val	His	Ile	Ser	Gln	Ser	Met	Asn	Ala	Ala	Ser	
					195										205		
Ser	Gly	Thr	Ser	Arg	200	Arg	Ser	Ser	Thr	Leu	Phe	Arg	Trp	Gln	Ser	Pro	
					210										220		
Cys	Met	Ile	Pro	Gly	215	Ser	Ala	Ser	Ser	Gly	Leu	Arg	Glu	Ser	Ser	Gln	
					225										240		
Ser	Ala	Ser	Thr	Cys	230	Thr	Asp	Gly	Asn	Asp	Ser	Gly	Ala	Gly	Ser	Asp	
					245										255		
Gln	Leu	Gly	Glu	Pro	245	Gly	Ala	Gln	Gln	Arg	Gln	Arg	Gly	Lys	His	Arg	
					260										270		
Asp	Arg	Arg	Asp	Asp	265	Val	Pro	Ala	Gln	Gln	Arg	Pro	Ala	Val	His	Pro	Ala
					275										285		
Gly	Pro	Gly	Pro	Ala	275	Asp	Arg	Val	Gly	Val	Asp	Pro	Gly	Arg	His	Arg	
					290										300		
Arg	Ala	Arg	Gly	Gln	295	His	Gln	Pro	Arg	Asp	Gly	Ser	Asp	Arg	Gln	Ala	
					305										320		
Ser	Arg	Thr	Val	Ser	310	Gly	Val	Pro	Val	Glu	Ser	Asn	Val	Leu	Ser	Ala	
					325										335		
Gly	Ile	Arg	Cys	Arg	340	Thr	Pro	Thr	Thr	Arg	Ala	Val	Ala	Ile	Cys	Leu	
					345										350		
Ala	Thr	Leu	Ala	Ser	355	Arg	Gly	Val	Val	Ala	Pro	Gln	Pro	Ala	Gly	Asp	
					360										365		
Val	Ala	Arg	Ala	Ala	370	Ala	Ala	Gly	Ser	Pro	Trp	Pro	Val	Arg	Ser	Val	
					375										380		
Ala	Arg	Pro	Val	Ala	385	Val	Leu	Arg	Thr	Gly	Pro	Pro	Pro	Arg	Arg	Pro	
					390										400		
Ser	Asp	Thr	Gly	Ser	405	Ile	Thr	Gln	Val	Gly	Arg	Pro	Ala	Val	Leu	Phe	
					410										415		
Ala	Pro	Glu	Gln	Arg	420	Cys	Arg	Arg	Ala	Asp	Gln	Arg	Ser	Cys	Arg		
					425										430		
Gln	Ile	His	Pro	Gly	435	Gly	Gly	Arg	His	Val	Gln	Ile	Val	Ala	Ser	Ala	
					440										445		
Arg	Gly	Thr	Val	Glu	450	Ile	Gly	Ser	Ile	Ala	Arg	Leu	Cys	Gly	Lys	Asp	
					455										460		
Glu	Ala	Val	Ala	Ala	465	Leu	His	Tyr	Val	Ala	Pro	Val	Gly	Glu	Lys	Gln	
					470										480		
Asp	Tyr	Ile	Asp	Arg	485	Ala	Leu	Arg	Asn	Ile	Gly	Pro	Tyr	Leu	Pro	Ala	
					490										495		
Glu	Val	Pro	Ala	Leu	500	Val	Gly	Ser	Ile	Ala	Ala	Thr	Gly	Pro	Val	Pro	
					505										510		
Gly	Thr	Ala	Trp	Ile	515	Val	Arg	Gln	Tyr	Pro	Lys	Leu	Leu	Arg	Ala	Lys	
					520										525		
Ala	Asn	Trp	Glu	Asp	530	Thr	Trp	Thr	Phe	Pro	Ser	Ile	Glu	Glu	Lys	His	
					535										540		
Arg	Pro	Arg	Gly	Ser	545	Val	Ala	Gly	Pro	Val	Phe	Arg	Val	Asn	Leu	Gly	
					550										560		
Arg	Ala	Ile	Pro	Ser	565	Arg	Ala	Ala	Arg	Ala	Ala	Glu	Ile	His	Gly	Ser	
					570										575		
His	His	His	His	His	580												

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NZ00/00121

A. CLASSIFICATION OF SUBJECT MATTER																						
Int. Cl. C07K 7/06, 7/08; C07H 21/00; A61K 38/08, 38/10, 38/16																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
B. FIELDS SEARCHED																						
Minimum documentation searched (classification system followed by classification symbols)																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) ANGIS: (FASTA) SEQ ID NOS 61-77																						
C. DOCUMENTS CONSIDERED TO BE RELEVANT																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
X	GenPept Database entry, Accession AAA72555, 1985 See sequence	2(a)(b)[seqs 61-63], 3-25																				
X	GenPept Database entry, Accession AAB38132, 1996 See sequence	2(a)[seq 68], 3-25																				
X	GenPept Database entry, Accession AAC32046, 1998 See sequence	2(a)(b)[seq 77], 3-25																				
X	GenPept Database entry, Accession AAC70256, 1999 See sequence	2(a)(b)(c)[seq 64], 3- 25																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C		<input type="checkbox"/> See patent family annex																				
<p>* Special categories of cited documents:</p> <table> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier application or patent but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 14 November 2000	Date of mailing of the international search report 28 NOV 2000																					
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606. AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorised officer G. D. HEARDER Telephone No : (02) 6283 2553																					

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NZ00/00121

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GenPept Database entry, Accession AAD34368, 1999 See sequence	2(a)(b)(c)[seq 68], 3-25
P, X	GenPept Database entry, Accession AAF10382, 1999 See sequence	2(a)[seq 74], 3-25
X	SWISS-PROT Database entry Accession ID ATPF_BACCA, 1995 See Sequence	2(a)(b)[seq 68], 3-25
X	GenPept Database entry, Accession BAA97474, 1999 See Sequence	2(a)[seq 69], 3-25
X	GenPept Database entry, Accession CAB07541, 1995 See sequence	2(a)[seqs 67, 72], 3-25
X	GenPept Database entry, Accession CAB45489, 1996 See sequence	2(a)(b)[seq 70], 3-25
X	TREMBL Database entry, Accession E1263321, 1998 See sequence	2(a)[seq 77], 3-25
X	TREMBL Database entry, Accession E968234, 1998 See sequence	2(a)(b)(c)[seqs 61-63], 3-25
X	SWISS-PROT Database entry, Accession ID HEM0_RHOSH, 1996 See sequence	2(a)[seq 76], 3-25
X	SWISS-PROT Database entry, Accession ID MTBR_BACSU, 1988 See sequence	2(a)[seq 65], 3-25
P, X	TREMBL Database entry, Accession Q9S9B2, 2000 See sequence	2(a)[seq 67], 3-25
P, X	PIR Database entry, Accession T28682, 1999 See sequence	2(a)[seq 75], 3-25
P, X	PIR Database entry, Accession T46707, 2000 See sequence	2(a)[seq 71], 3-25
X	SWISS-PROT Database entry, Accession ID YO1J_CAEEL, 1998 See sequence	2(a)[seq 70], 3-25

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ00/00121

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos : because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos : 3-25 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: For economic reasons only sequences 61-77 were searched. However the results of this search (in looking for sequences that fall within the scope of claim 2) were too many to include in this ISR. Hence the citations that appear in this ISR are only a selection of many possible citations. For a specific summary of the results please see the extra sheet.
3. Claims Nos : because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ00/00121

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: I.2.

Summary of search results (for claim 2):

The citations that appear in the list of documents considered to be relevant above, are only a selection from the numerous results below (ie one from each category):

This table represents the number of sequences that fall within the specific parts of claim 2 for each of sequences 61-77.
 [Note: (a) falls within the scope of (b) which falls within the scope of (c) which falls within the scope of (d)]

	SEQ ID NOS																
	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77
Claim 2(a)	0	0	0	X	15	X	15	2	5	16	10	4	0	2	8	16	15
Claim 2(b)	1	1	1	X	0	X	0	17	0	1	0	0	0	0	0	0	1
Claim 2(c)	19	19	19	1	0	0	0	1	0	0	0	0	0	0	0	0	0
Claim 2(d)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

("X" denotes that it was not searched as it was outside the scope of the claim)

Thus there are no citations against Claim 2(d), (and claim 1), and numerous citations against claim 2 (a), (b) and (c).